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ABSTRACT 
The present study investigated the impact of personality pathology on adherence and 
treatment response to a novel group-based intervention for depression, Therapeutic 
Lifestyle Change (TLC).  Based on existing empirical literature documenting poor 
adherence and treatment outcome associated with comorbid Axis II pathology, patients 
with elevated levels of personality pathology were expected to exhibit less adherence and 
response to TLC for depression.  Contrary to expectations, however, no significant 
association between Axis II pathology and treatment adherence was observed.  It is 
possible that certain features of TLC, such as its highly structured approach, may 
facilitate adherence among personality-disordered patients.  Nevertheless, despite similar 
levels of treatment adherence in comparison with the rest of the study sample, patients 
with elevated levels of personality pathology on either Cluster A or Cluster B responded 
significantly less well to TLC, even when controlling for initial depression severity. 
Failure of TLC elements to adequately target important features of Cluster A and Cluster 
B pathology, such as affective dysregulations and substantial interpersonal difficulties, 
may be responsible, in large part, for the observed differential treatment response.  
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The Impact of Personality Pathology on Treatment Response to 
 
Therapeutic Lifestyle Change (TLC) for Depression 
 
 
 Depression is a burgeoning public health problem (Keller & Boland, 1998; 
NIMH, 1999), with an estimated lifetime prevalence rate in the U.S. of approximately 
25% (Kessler et al., 2005).   In fact, more than 19 million adult Americans now 
experience depressive illness each year (Ingram, Scott, & Siegle, 1999; National Institute 
of Mental Health, 1999).  Depression is increasingly viewed as a chronic, lifelong 
condition marked by recurring cycles of recovery and relapse (Frank et al, 1991; Grilo et 
al., 2005; Mueller et al., 1999), with each successive episode of illness characterized by 
symptomatology of increasing severity (Thase & Howland, 1994).  Accordingly, the 
disorder is now projected to become the second overall cause of disability worldwide by 
the year 2020 (Murray & Lopez, 1996). 
  A large proportion of depressed individuals suffer from co-occurring personality 
disorders (PD) (Ilardi & Craighead, 1995), which adversely affect cognition and 
occupational and social functioning (Post, 1994; Young, Weinberger, & Beck, 2001).  
Personality disorders have been conceptualized as the presence of enduring patterns of 
perception, cognition, and behavior that are generally inflexible and maladaptive and 
cause either significant functional impairment or subjective distress (American 
Psychiatric Association, 1987).  The Diagnostic and Statistical Manual of Mental 
Disorders, 4th edition (DSM-IV; American Psychiatric Association, 1994) groups Axis II 
disorders into three clusters according to shared characteristics or features.  Cluster A, 
characterized by “odd” and “eccentric” cognition and behavior, is comprised of 
schizotypal PD, schizoid PD, and paranoid PD.  Cluster B, labeled as the “dramatic” and 
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“erratic” cluster, encompasses borderline PD, antisocial PD, narcissistic PD, and 
histrionic PD.  Finally, cluster C, characterized by “anxious” and “fearful” thinking and 
behavior, includes avoidant PD, dependent PD, and obsessive-compulsive PD.   
The high degree of comorbidity between depression and PD has been documented 
by a number of researchers, with observed co-occurrence rates generally ranging from 
35% to 87% (Charney et al., 1981; Friedman et al., 1983; Hardy et al., 1995; Shea et al., 
1987).  This high prevalence of PD in depressed populations has generated considerable 
interest in the relationship between depression and personality pathology, and several 
hypotheses have been proposed.  Due to its potential clinical utility, the pathoplasty 
model (Klein, Wonderlich, & Shea, 1993; Shea & Yen, 2005) has informed the majority 
of research in this area.  This model assumes distinct etiology, but emphasizes the 
influence of each co-occurring condition on the presentation and clinical course of the 
other.  In other words, personality pathology may influence the way in which depression 
is experienced and expressed, and depression may in turn exacerbate the manifestation of 
the personality pathology. 
 
ACUTE TREATMENT OUTCOME FOR DEPRESSION 
The introduction of a separate axis for the diagnosis of personality disorders in the 
DSM-III (American Psychiatric Association, 1980) brought about a widely accepted 
conceptualization of PDs and depression as distinct disorders.  Consequently, there has 
been a steady increase in interest in the influence of PD’s on the general course of 
depression, with a particular focus upon treatment response (Shea et al., 1992).   The 
majority of researchers and clinicians have shared the assumption that the co-occurrence 
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of Axis II disorders and depression may have a deleterious effect on treatment outcome.  
Given the definition of PDs as enduring, inflexible maladaptive patterns of thinking, 
behaving, and feeling, it would appear logical to infer that individuals with such 
characterological dysfunction could prove more difficult to treat, and less responsive to 
clinical interventions (Saulsman, Coall, & Nathan, 2006). 
Early studies in this area primarily focused on somatic treatments for depression 
(e.g., antidepressant medications), and these studies generally confirmed the hypothesis 
of PD’s exerting a negative impact on the treatment outcome (Farmer & Nelson-Gray, 
1990; Kuyken, 2001; Perry, Banon, & Ianni, 1999; Persons & Burns, 1985; Persons, 
Burns, & Perloff, 1988; Pilkonis & Frank, 1988; Reich & Green, 1991; Reich & Vasile, 
1993; Whisman, 1993).  Shea and colleagues (1992) noted in their review that the 
majority of published findings support the common belief that PD’s are associated with 
poorer response to both pharmacologic and psychotherapeutic treatment of depression.  
The authors also observed a clinical acceptance of the belief that individuals with PD’s 
are typically unresponsive to pharmacotherapy. 
  Interestingly, in a study of 160 depressed inpatients, Charney et al. (1981) 
observed that 71% of non-comorbid depressed patients had been prescribed 
antidepressants compared with only 28% of comorbid PD and depressed patients.  Shea 
and colleagues (1992) hypothesized this treatment discrepancy is due largely to the 
common belief among clinicians that depression with comorbid PD represents a distinct, 
perhaps less biologically-based, disorder (Akisal, Hirschfeld, & Yerevanian, 1983).  
Thus, individuals with comorbid depression and PD – who typically struggle with 
considerable interpersonal difficulties along with social and occupational impairment – 
 4
have been historically viewed as less amenable to treatment with pharmacotherapies 
designed to address dysregulations in neurotransmission in the central nervous system 
(Ilardi & Craighead, 1995).  Consequently, many early researchers regarded somatic 
treatments, relative to psychotherapeutic treatments, as less effective in treating 
individuals with depression and comorbid PD.  Furthermore, Shea and colleagues (1992) 
suggested that the presence of personality pathology and its consequences (e.g., 
difficulties with interpersonal relationships, lack of adequate social support, high level of 
perceived life stressors, etc.) complicates response to treatment, makes afflicted patients 
more resistant to treatment in general, and leaves them with a persistent vulnerability to 
future depressive episodes.   
Ilardi and Craighead (1995) conducted a review of the relevant literature that 
corroborated the conclusions of Shea and colleagues (1992).  These investigators found 
robust evidence, based on 14 empirical studies, that Axis II disorders predict relatively 
poor outcomes with somatic treatments (pharmacotherapy and ECT), both acutely and in 
the long-term.  Moreover, the authors discovered a strong negative correlation between 
the total number of Axis II criteria met and overall pharmacologic treatment response, 
and an analysis of 7 additional studies that used non-DSM measures of personality 
pathology (e.g., neuroticism, dependency, etc.) yielded additional supportive evidence.  
However, the authors noted that insufficient evidence was available to conclude that 
specific personality disorders or clusters of disorders were associated with especially 
negative outcomes.     
The contention that comorbid Axis II PD predicts relatively poorer response to 
treatment for depression has not gone unchallenged.  Mulder (2002, 2004; Mulder, Joyce, 
 5
& Luty, 2003) has written several reviews asserting that, although clinical intuition and 
early studies assume a sense of pessimism associated with comorbid PD and depression, 
empirically the answer is not so clear. He suggests that depressed individuals with 
comorbid PD “fare little if any worse” compared to depressed individuals without co-
occurring PD (Mulder, 2002; 2004), and that significant differences in treatment outcome 
cited in past reviews are simply attributable to differences in study design.  Furthermore, 
Mulder avers that the best-designed studies (i.e., ones that utilized randomized controlled 
trials and structured interview for personality pathology assessment) reported the least 
effect of personality pathology on treatment outcome for depression.  Thus, Mulder 
(2004) concludes that the negative effect of co-occurring PD on treatment outcome for 
depressed individuals may be less robust than previously believed.   
Reich (2003), however, has strongly challenged Mulder’s claims.  In his review of 
11 relevant studies that have used psychometrically sound diagnostic instruments to 
confirm the presence of Axis II pathology, Reich (2003) found that all but one study 
observed a significantly poorer response to treatment of depression among individuals 
with comorbid PD.  This phenomenon appears to be driven in part by the tendency of 
Axis II co-morbid patients to experience higher rates of treatment dropout.  Although 
Reich noted that no PD has been differentially associated with especially poor 
antidepressant response, the magnitude of overall symptom reduction tends to covary 
inversely with an additive (dimensional) measurement of PD traits across all Axis II 
disorders.  Notably, a recent meta-analysis of the relevant literature (Newton-Howes, 
Tyrer, & Johnson, 2006) lends support to Reich’s (2003) position.  Aggregating across all 
studies, Newton-Howes and colleagues observed poor treatment response among 
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approximately 55% of individuals with co-occurring PD, compared with an 
unsatisfactory response among only 45% of individuals without comorbid PD.   
As noted previously, reviews of the effect of personality pathology upon 
treatment outcome have largely focused on psychopharmacological treatments for 
depression.  Increasingly, though, researchers have turned their attention to the influence 
of comorbid PD on outcomes in psychotherapy for depression, with a particular focus on 
cognitive-behavior therapy (CBT).  Given the established efficacy (Beck, Rush, Shaw, & 
Emery, 1979; Dobson, 1989; Hollon, Shelton, & Loosen, 1991) and widespread use (De 
Rubeis & Crits-Christoph, 1998) of CBT to treat depression, it is no surprise that a 
growing number of studies exploring the impact of co-occurring PD on the treatment 
response of CBT for depression are emerging in the empirical literature.   
Shea and colleagues (1990) evaluated the relationship between PD and treatment 
outcome in the NIMH Treatment of Depression Collaborative Research Program 
(TDCRP).  The authors reported that patients without PD responded better to treatment 
(i.e., had lower depression scores at termination) than patients with comorbid PD in all 
treatment conditions, except in the CBT treatment condition.  That is, in the CBT 
condition the patients with comorbid PD actually performed slightly better than the 
patients without PD.  This finding was certainly unexpected and stimulated interest in the 
research field.   
 Moreover, a recent review (Hirani, 2007) provided substantial evidence that the 
presence of a co-occurring PD does not appear to have an adverse impact on treatment 
response to CBT for depression.  That is, eight out of the ten studies that have 
investigated the impact of Axis II PD on the response to CBT for depression reported that 
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the rates of improvement in depressive symptomatology in patients with and without co-
occurring PD were not significantly different (Hardy et al., 1995; Kuyken, Kurzer, 
DeRubeis, Beck, & Brown, 2001; Patience, McGuire, Scott, Freeman, 1995; Persons, 
Burns, & Perloff, 1988; Saulsman, Coall, & Nathan, 2006; Shea et al., 1990; Stuart, 
Simons, Thase, & Pilkonis, 1992; Van den Hout, Brouwers, & Oomen, 2006) 
 The review (Hirani, 2007) noted that a majority of the studies reported elevated 
posttreatment depression scores for patients diagnosed with comorbid Axis II disorders 
compared to patients without an Axis II disorder; however, these studies also generally 
observed a comparable elevation of pretreatment depression scores for the PD groups.  
Thus, although the patients with comorbid PD exhibited more residual depressive 
symptomatology, the rate of improvement was similar.  In the end, the reviewed studies 
provide considerable evidence that the presence of a comorbid Axis II disorder did not 
significantly impact treatment response to CBT for depression. 
The reason for the differential treatment response of CBT in treating depression in 
patients with co-occurring PD compared to other treatments remains unclear.  It is 
perhaps plausible to infer that CBT is specifically beneficial in the treatment of 
depression in individuals with comorbid PD largely because of its highly structured, 
time-limited, and problem-focused nature (Freeman, Pretzer, Flemming, & Simon, 1990; 
Patience, et al., 1995, Shea, et al., 1990).  That is, because patients with co-occurring PD 
and depression tend to experience affective dysregulation, substantial interpersonal 
difficulties, and multiple crises (Zaretsky, Rosenbluth, & Silver, 2005), they may be more 
responsive to a direct approach that facilitates the separation of problems into specific 
tasks and allows for the addressing of depressive symptomatology before attending to 
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more complex personality difficulties (Hardy et al., 1995).  Finally, Beck and Freeman 
(1990) have posited that, unlike individuals suffering solely from Axis I MDD, depressed 
individuals with comorbid Axis II PD experience chronic activation of negative schemas 
even when they are not severely depressed.  If this in indeed the case, then the decrease in 
depressive symptomatology following CBT for this population may be directly related to 
the modification of their dysfunctional belief system and the development of new 
strategies to help them expand their perception of distressing situations and become more 
flexible in their response to stress.   
 An examination of the empirical literature reveals that far less attention has been 
given to the evaluation of the impact of comorbid PD on treatment outcomes in 
interpersonal psychotherapy (IPT) and psychodynamic psychotherapies for depression.  
Nevertheless, the majority of relevant studies have identified the presence of co-occurring 
PD as a negative prognostic indicator in the treatment of depression.  The large-scale 
NIMH TDCRP study (Shea et al., 1990), for example, observed that comorbid PD 
adversely affected treatment response of IPT for depression.  In two other randomized 
controlled trials, Frank and colleagues treated outpatients diagnosed with recurrent 
unipolar depression with imipramine and IPT, and they observed that the presence of a 
comorbid PD was associated with a significantly slower response to treatment (Frank, 
Kupfer, Jacob, & Jarrett, 1987; Pilkonis & Frank, 1988).  In addition, a study of 76 
depressed outpatients treated with IPT reported that patients with greater co-occurring 
personality pathology were significantly less likely to respond to IPT for depression 
(Bearden, Lavelle, Buysse, Karp, & Frank, 1996).   
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 Likewise, studies investigating the effect of co-occurring PD on the treatment 
response of psychodynamic psychotherapy for depression have typically observed 
significantly poorer outcomes for PD clients than NPD clients.  Hoffart and Martinsen 
(1993), for example, treated 77 depressed inpatients with psychodynamic psychotherapy.  
The authors reported worse outcome in terms of post-treatment depression severity for 
dependent PD and paranoid PD.  Moreover, depressed patients with comorbid avoidant 
PD reported significantly more depression symptomatology at 1-year follow-up 
compared to depressed patients without PD (Hoffart & Martinsen, 1993).  Furthermore, 
Hardy et al. (1995) reported that depressed patients with comorbid Cluster C PD’s 
demonstrated a less favorable response to psychodynamic interpersonal psychotherapy 
vis-à-vis post-treatment BDI.    
 The evidence in support of a negative effect of comorbid PD on acute treatment 
outcome of depression in electroconvulsive therapy (ECT) does not appear to be as 
robust compared to that found for other treatments for depression.  For example, Pfohl, 
Stangle, & Zimmerman (1984) reported that depressed patients with comorbid PD 
responded as well as NPD patients to ECT.  In their review, Ilardi and Craighead (1995) 
pointed out that the findings from the (ECT) studies available were less conclusive, but a 
meta-analysis suggested a relatively poorer outcome for individuals with co-occurring 
depression and PD.  Moreover, DeBattista and Mueller (2001) asserted in their review 
that the presence of a co-occurring PD, especially borderline PD (BPD) was associated 
with a less favorable treatment response to ECT.  In a more recent review, Mulder (2002) 
noted that, although there was a trend towards worse outcome in all the studies reviewed, 
the presence of a comorbid PD did not significantly impact ECT treatment outcome for 
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depression.  Finally, Newton-Howes, Tyrer, and Johnson (2006) conducted a meta-
analysis and concluded that comorbid PD was associated with a relatively poorer 
treatment outcome for all treatments of depression (i.e., psychotherapies and 
pharmacotherapies) with the exception of ECT.  
 
LONG-TERM TREATMENT OUTCOME FOR DEPRESSION 
 Several studies have provided support for the hypothesis that comorbid PD has a 
deleterious effect on not only acute treatment outcome for depression, but also for longer-
term treatment outcome.  Thompson, Gallagher, and Czirr (1988), for example, treated 
patients with late-life depression with cognitive therapy (CT), behavior therapy, or brief 
psychodynamic therapy and followed them for 2 years after treatment completion.  The 
authors (Thompson, Gallagher, & Czirr, 1988) reported that the presence of a co-
occurring PD was a risk factor for depression following treatment.  In addition, Ilardi & 
Craighead (1995) reported in their review that the presence of a comorbid Axis II 
disorder was associated with an increased chance of relapse following pharmacological 
treatments for depression.  Furthermore, in a naturalistic study that followed depressed 
patients for 2-years, Viinamaki et al. (2003) reported that comorbid Cluster C PD was 
associated with inferior recovery compared to depressed patients in the absence of any 
PD.  Grilo and colleagues (2005) also conducted a naturalistic 2-year follow-up and 
concluded that co-occurring PD predicted slowed remission from major depressive 
disorder (MDD) even when controlling for negative prognostic indicators, such as total 
number of Axis I disorders, dysthymia, single versus recurrent MDD, and age of onset of 
MDD.  It should also be noted, however, that a recent review reported that co-occurring 
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PD was not associated with significantly reduced maintenance of treatment gains 
following CBT for depression (Hirani, 2007).   
 
EFFECT OF PD ON ADHERENCE 
 Treatment noncompliance is a serious issue across intervention modalities, and it 
has been asserted that the major reason for the discrepancy between efficacy and 
effectiveness of treatments for psychological disorders is poor treatment adherence 
(Sajtovic, Davies, & Hrouda, 2004).  Cahalane (1997) noted that as few as 28% of clients 
requesting services at outpatient mental health clinics actually complete a course of 
treatment.  Also, in a large study of inpatients and outpatients diagnosed with MDD, 
Melartin et al. (2005) observed that 49% of patients who were prescribed antidepressants 
terminated their treatment prematurely.  Moreover, nonadherence has been closely 
associated with poorer treatment outcome, relapse, rehospitalization, and suicide among 
patients with major mental illness (Colom & Vieta, 2002; Delaney, 1998; Muller-
Oerlinghausen, Muser-Causemann, & Volk, 1992; Scott, 2000).   
 A number of studies have documented an adverse impact of PD on adherence to 
several treatments.  Ilardi and Craighead (1995) note that depressed patients with co-
occurring PD, especially Cluster B, are more prone to medication noncompliance.  They 
also point out that depressed patients with comorbid PD seem to respond slower to 
antidepressants, perhaps due to poor adherence to prescribed medication schedules.  In a 
similar vein, Sajtovic et al. (2004) reported in their review that the presence of comorbid 
PD is associated with less adherence to medication and psychotherapy in patients with 
bipolar disorder.   
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  A negative effect of comorbid PD on treatment adherence has also been observed 
in studies evaluating psychotherapeutic treatments for Axis I disorders.  Persons, Burns, 
and Perloff (1988), for example, reported that Axis II pathology predicts premature 
termination from CT for depression.  In addition, Cahalane (1997) reported that co-
occurring PD predicted significantly poorer adherence to CBT treatment for anxiety 
disorders.  Furthermore, Andreoli et al. (1989) reported that comorbid PD was associated 
with significantly poorer working alliance with the therapist and higher incidence of 
dropout in inpatients treated for Axis I disorders. 
 The literature on substance use disorders (SUD) provides robust evidence for the 
negative impact of comorbid PD on treatment adherence.  Herbeck and colleagues (2005) 
investigated treatment adherence in 342 SUD outpatients seen in routine psychiatric 
practice; the authors reported that co-occurring PD was the strongest predictor of 
treatment compliance problems.  Furthermore, in a review of 22 studies, Havens and 
Strathdee (2005) concluded that the presence of antisocial PD (ASPD) was associated 
with significantly poorer treatment adherence to opiod treatment.   
 Personality pathology has also been shown to have a negative impact on 
adherence to certain behavioral elements that have exhibited antidepressant effects, such 
as exercise and sleep (Dunn, Trivedi, Kambert, Clark, & Chambliss, 2005; Kuo, Manber, 
& Loewy, 2001; Mather et al., 2002; Morawetz, 2003).  A meta-analysis of 15 studies, 
for example, concluded that certain personality traits that are characteristic of individuals 
with PD (e.g., insecurity, social introversion, psychasthenia, etc.) were associated with 
less exercise adherence (McDonald & Hodgdon,  1991).   
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In addition, several published studies have demonstrated a positive association 
between personality pathology and disturbed sleep patterns.  A recent study of sleep 
patterns among college students reported that people with poor sleep quality are less 
emotionally stable, less self-assured, less observing of rules and regulations, more 
skeptical of the motives of others, and have higher trait anxiety (Jenkins, 2005).  Again, 
these traits are often observed in PD individuals who, by definition, struggle with 
interpersonal relationships and social functioning.  In addition, Philipsen and colleagues 
(2005) reported that individuals with BPD exhibited depression-like REM sleep 
abnormalities.  A similarity in EEG sleep profile between BPD and depressed patients 
was also observed by Aasad, Okasha, & Okasha (2002) suggesting a common biological 
origin for both disorders.  Finally, Dagan and colleagues (1996) reported that the 
presence of a PD predicted a higher incidence of circadian rhythm sleep disorder (CRSD) 
diagnosis compared to a control group.  Thus, personality pathology has been shown to 
predict poor adherence to not only numerous somatic and psychotherapeutic treatments 
for Axis I disorders, but also for documented antidepressant elements, such as exercise 
and sleep.  Accordingly, it is reasonably hypothesized that this adverse effect of 
comorbid PD on treatment adherence is directly related to the relatively poorer treatment 
response observed in this population.   
 
HYPOTHESIZED MECHANISMS 
Several theories have been forwarded to explain the adverse impact of Axis II 
disorders on treatment adherence and outcome.  For instance, Persons and Burns (1985) 
asserted that the higher incidence of dropout among depressed patients with comorbid PD 
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may be due to the relative lack of emotional improvement experienced during individual 
CT sessions.  Kernberg (1975) posited that higher rates of dropout among comorbid PD 
and depressed patients can be attributed to transference and countertransference problems 
encountered in this population.  In addition, it has been suggested that elevated levels of 
defensiveness to problems coupled with less motivation for change results in poorer 
treatment adherence and outcome in patients with co-occurring Axis II disorders.  
Furthermore, dropout among patients with PD and depression has been viewed as an 
expression of resistance to change or to the treatment process (Persons, Burns, & Perloff, 
1988). 
As noted earlier, it has been proposed that individuals with comorbid PD and 
depression experience elevated levels of depressotypic cognition even when they are not 
in a depressive episode (Beck & Freeman, 1990).  According to this theory, Axis II 
disordered patients have depressive schemas that are continually activated causing them 
to perceive and process daily information in a biased manner.  Consequently, this stable 
cognitive bias results in a propensity to experience dysphoric mood and residual 
depressive symptoms even in the absence of a full-blown depressive episode.  
Furthermore, it has been suggested that this depressotypic cognitive bias that is 
characteristic of patients with PD results, in part, in the perception and experience of 
more negative life events than NPD individuals.  This depressotypic bias and higher 
prevalence of experienced negative life events may serve as a risk factor for depression 
onset, maintenance, and relapse in this population. 
Hypothesized mechanisms for the adverse Axis II-related outcomes observed in 
many studies also include the interpersonal difficulties and problems in social functioning 
 15
characteristic of individuals with PD (Pfohl, Stangle, & Zimmerman, 1984; Shea et al., 
1990).  Shapiro (1978), for example, posited that increased observed rates of premature 
termination among depressed patients with borderline PD (BPD) are due to the 
characteristic perception among such patients of the therapist being insufficiently 
responsive to emotional needs.  In addition, Cahalane (1997) pointed out that the 
interpersonal difficulties characteristic of individuals with PD limit the ability of these 
individuals to develop and maintain a working alliance with the therapist.  Moreover, 
difficulties with trust observed in many patients with avoidant PD, paranoid PD, and 
BPD, may result in an anticipation of disappointment or rejection from the therapist; 
thereby, precluding a meaningful connection with the therapist and comparable treatment 
gains with patients without Axis II disorders.  Also, the fear of being controlled by the 
therapist or the fear of giving up on secondary gains (e.g., the need to be taken care of) 
may also be related to the higher incidence of noncompliance and poor treatment 
response in patients with PD (Persons, Burns, & Perloff, 1988).  Finally, the difficulties 
in developing and maintaining healthy interpersonal relationships typically observed in 
patients with PD results in the experience of less social support, less marital status, and 
lower quality of family relationships (Ilardi & Craighead, 1995; Shea, Widiger, & Klein, 
1992).  As social support has been shown to serve as a “buffer” for relapse of depression 
(George, 1989), it appears that the absence of adequate social support experienced by 
most individuals with PD leaves these patients vulnerable to future episodes of 
depression.  
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THERAPEUTIC LIFESTYLE CHANGE (TLC) FOR DEPRESSION 
 A clinical research team at the University of Kansas, headed by Dr. Stephen 
Ilardi, has developed of a novel treatment approach to depression based upon the 
introduction of six distinct lifestyle elements that have been independently shown to be 
efficacious in the treatment and prevention of depression – exercise (Blumenthal et al., 
1999; Dunn, Trivedi, Kambert, Clark, & Chambliss, 2005; Fremont & Craighead, 1987; 
Mather et al., 2002), omega-3 fatty acid supplementation (Nemets, Stahl, & Belmaker, 
2002; Peet & Horrobin, 2002), bright light exposure (Martiny, Lunde, Unden, Dam, & 
Bech, 2005), enhanced sleep (Morawetz, 2003; Kuo, Manber, & Loewy, 2001), anti-
ruminative activity (Fennell & Teasdale, 1984; Gibbons, et al., 1985), and social support 
(Ezquiaga, Garcia, Pallares, & Bravo, 1999; George, 1989; Oxman, Berkman, Kasl, 
Freeman, & Barrett, 1992).  The evolutionarily informed conceptual framework and 
rationale for TLC have been detailed elsewhere (Ilardi et al., 2005; Ilardi, Karwoski, 
Lehman, Stites, & Steidtmann, 2006; Karwoski, 2006).  Nevertheless, a brief overview of 
the treatment is warranted. 
 TLC is a 15-week, 12-session group protocol that was developed as a response to 
the recent epidemic of depression observed in developed nations.  The treatment is based 
on the theory that the significant rise in prevalence of depression (Seligman, 1988) is a 
result of the fundamental mismatch between the way our bodies are designed and the 
modern, post-industrial environment in which we live (Bowlby, 1969).  That is, inasmuch 
as the human genus has spent 99% of its existence in a hunter-gatherer context, the 
human body is best adapted to an environment that differs in numerous key respects with 
that of the 21st-century developed world.   
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The incidence of depression among modern hunter-gatherer bands appears to be 
extremely low (e.g., Schieffelin, 1985), and may have been similarly low in ancestral 
times as a result of protective elements inherent to that milieu.  Members of hunter-
gatherer societies lived among small groups of people which afforded them close contact 
and social support.  Also, these individuals engaged in significantly more exercise 
compared to individuals living in the modern environment as they were required to 
continually be active in order to obtain food and survive.  In addition, their being outside 
for the majority of each day resulted in a considerable amount of bright light exposure in 
the form of sunlight.  As there was no electricity, our human ancestors often retired to 
bed when the sun went down – resulting in significantly longer sleep duration in 
comparison with people living in modern industrialized contexts.  Furthermore, the diets 
of people living in ancestral times were significantly different from diets typical in 
developed societies, namely in the dramatically higher comsumption of dietary omega-3 
fatty acids – much of it derived from wild game and fish.  Finally, it is believed that the 
relative absence of social isolation among hunter-gatherers renders them much less likely  
to ruminate (i.e., to engage in repetitive negative thinking), a process shown to predict the 
onset of depressive episodes, as well as the severity and chronicity of depressive 
symptoms (Just & Alloy, 1997; Lam, Smith, Checkley, Rijsdijk, & Sham, 2003).  In 
short, we as humans have adapted to the hunter-gatherer context in which we have spent 
nearly all of our existence.  Consequently, the significant reduction in elements that are 
believed to have “naturally” limited the incidence of depression, as clinical depression 
does not confer any fitness advantages, in our modern, post-industrial environment has 
led to an epidemic of depression. 
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Hence, the promotion of the six lifestyle elements in TLC might serve to 
significantly reduce depressive symptomatology.  Indeed, initial evaluation of the TLC 
protocol has documented impressive results (Karwoski, Stites, Lehman, & Ilardi, 2007), 
with 86% of depressed individuals treated with TLC experiencing a favorable treatment 
response, in comparison with a response rate of 22% among waitlist controls who 
received treatment-as-usual in the community.  
 
PRESENT STUDY 
Numerous reviews have identified the presence of co-occurring Axis II pathology 
as a marker of poor depression treatment response and increased probability of relapse 
following treatment (e.g., Ilardi & Craighead, 1995; Reich & Green, 1991; Shea et al., 
1992).  Some more recent reviews, however, have brought this long-standing belief into 
question (Hirani, 2007; Mulder, 2002).  In an attempt to facilitate a better understanding 
of the impact of comorbid Axis II disorders on the response to treatment for depression, 
the present study examined the effect of co-occurring personality disorders on the 
adherence and treatment outcome of a promising, novel treatment for depression, TLC 
(Ilardi et al., 2005; Ilardi et al., 2007). 
It is the responsibility of researchers in this field to determine what treatment 
works, for whom, and under what circumstances.  This quest encompasses sound 
investigations aimed at uncovering factors that are (and are not) responsible for 
heterogeneity in treatment response.  Thus, the impact of comorbid personality disorders 
on TLC treatment adherence and outcome for depression constitutes an important 
scientific question with significant clinical implications.  In short, the presence of an Axis 
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II disorder may have considerable consequences vis-à-vis treatment planning.  It is 
possible that typical TLC alone may not be sufficient for the adequate and effective 
treatment of many depressed patients with co-occurring PD. 
The present study addressed several methodological issues that have been 
encountered in this research domain (Mulder, 2002).  First, it statistically controlled for 
important clinical characteristics of participants, such as initial severity of depression.  A 
reason for the aforementioned discrepancies in the published Axis II-depression literature 
may be due in part to the use of posttreatment depression scores alone (i.e., end-state 
functioning) to determine treatment outcome.  As noted earlier, these studies often failed 
to take into account that, although PD groups had significantly more depressive 
symptomatology at the end of treatment compared to depressed patients without PD, the 
rate of improvement was often equivalent due to the higher initial depression scores of 
the PD groups.  Moreover, an evaluation of more recent studies demonstrates an 
increasing acceptance of treatment outcome conceptualized as rate of improvement.  
Thus, this study statistically controlled for initial depression severity and defined 
treatment outcome as rate of improvement. 
Second, as relevant information is often lost with the exclusive employment of 
categorical variables, the proposed study utilized continuous personality pathology and 
outcome data in their analyses (Ilardi, Craighead, & Evans, 1997; Mulder, 2002).  Third, 
a structured interview (i.e., SCID-II) with documented validity and reliability (First, 
Spitzer, Gibbon, & Williams, 1995) was used to assess personality pathology.  The use of 
a structured interview, rather than a self-report measure or clinician’s chart review, is 
recommended for the assessment of Axis II PD as it is more valid, more reliable, and less 
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sensitive to the depressotypic cognitive bias that leads to overreporting of personality 
pathology associated with depressed mood (Mulder, 2002; Zimmerman, 1994).   
Fourth, in an effort to promote generalizability, depressed participants in the study 
were allowed to continue adjuvant pharmacotherapy for depression.  Fifth, data from 
participants who dropped out of treatment were included in the analyses.  It has been 
argued that eliminating dropout data ignores an important outcome variable (Reich, 
2003).  That is, if individuals with co-occurring PD and depression do worse in treatment 
because they drop out, it is still indicative of a difference in treatment response between 
depressed individuals with and without comorbid PD.  Finally, a series of multiple 
regression analyses and a macro (Preacher & Hayes, 2007) were employed to enable 
detection of a potential mediational role of TLC treatment adherence to treatment 
response.  That is, the present study informs the question of whether treatment adherence 
is the mechanism through which co-occurring PD has an effect on TLC treatment 
outcome. 
The pessimism generated by past reviews regarding the treatment response of 
patients with co-occurring depression and PD appears to be largely warranted.  Although 
recent reviews (e.g., Hirani, 2007; Mulder, 2002) report that the presence of co-occurring 
Axis II disorder does not significantly impact outcome for every treatment for depression, 
the empirical literature provides evidence that comorbid PD is a negative prognostic 
indicator for most treatments for depression.  Moreover, as noted previously, several 
studies have reported an adverse effect of PD on treatment adherence to 
pharmacotherapy, sleep, exercise, and various psychotherapies.  Thus, the hypotheses of 
the proposed study are enumerated as follows: 
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(1) the presence of comorbid personality pathology will be associated with less 
treatment adherence to TLC for depression;  
(2) the presence of comorbid personality pathology will be associated with poorer 
treatment response to TLC for depression;  
(3) treatment adherence to TLC will be associated with treatment response vis-à-
vis reduction in depressive symptomatology; and 
(4) the effect of comorbid personality pathology on treatment response will be 
mediated by treatment adherence.  
 
METHOD 
 The study methodology is identical in most respects to that detailed previously by 
Karwoski (2006).  However, unlike the previous investigation, the primary goal of this 
study is the evaluation of the effect of comorbid PD on TLC treatment adherence and 
outcome.  Thus, the key differences, primarily in the assessment of personality pathology, 
are clarified below. 
Participants 
 As described in Karwoski (2006), participants were recruited through fliers, 
community referrals, in-class announcements, and newspaper, magazine, and television 
coverage.  Interested individuals were called and screened by telephone.  In this initial 
screening, they were asked the first nine questions from the Structured Clinical Interview 
for DSM-IV Disorders (SCID; First, Spitzer, Gibbon, & Williams, 1997) mood module to 
determine the likelihood of their receiving a diagnosis of major depressive disorder.  
Likely candidate participants were invited to be evaluated in person by a trained graduate 
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level research assistant to determine eligibility.  This evaluation included completion of 
the SCID mood disorders, substance abuse, and psychotic disorders modules, the Beck 
Depression Inventory-II (BDI-II; Beck, Steer, & Brown, 1996) and Hamilton Rating 
Scale for Depression (HRSD, Hamilton, 1960) to determine baseline ratings of 
depressive symptomatology.  Subjects were eligible to participate if they received a 
current SCID-based diagnosis of major depressive disorder according to the DSM-IV 
diagnostic criteria, were between the ages of 18 and 65, and did not have psychotic 
symptoms, a substance abuse diagnosis, a history of self-harm behavior during the past 
two years, or active suicidal ideation.   
Measures 
 Participants were assessed by trained graduate students on the mood, substance 
abuse, and psychotic modules of the SCID.  The SCID is a structured interview which 
uses standardized clinician-directed queries designed to assess Axis I conditions 
including depression.  Research has provided evidence of the reliability of Axis I 
diagnoses assigned on the basis of the SCID, with inter-rater agreement kappas ranging 
from .70 to 1.00 in community and clinical samples (Segal, Hersen, & Van Hasselt, 
1994).  In fact, the SCID is considered the “gold standard” of diagnostic classification in 
clinical research settings due to this high level of inter-rater reliability. 
 Participants were also given the SCID-II (Spitzer, Williams, Gibbon, & First, 
1990) within the first 2 weeks of treatment.  The SCID-II is a clinician-administered 
structured interview for diagnosing the 11 Axis II personality disorders of the DSM-III 
with documented reliability and validity (First, Spitzer, Gibbon, & Williams, 1995).  It 
should be noted that depressive PD was not assessed as it is listed as a “candidate” Axis 
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II diagnosis in the DSM-IV appendix.  The SCID-II was given by a trained graduate 
student to diagnose PD in each participant.  In addition, dimensional scores of personality 
pathology for each individual cluster as well as overall personality pathology were 
computed from data obtained from the SCID-II assessment (First, et al., 1995).  These 
scores were computed by summing the number of personality disorder criterions rated as 
positive.  Specifically, 0 points were scored for a personality disorder criterion rated as 
“absent”, 1 point was scored for a criterion rated as “subthreshold”, and 2 points were 
scored for a criterion rated as “threshold”.  In general there are two or three interview 
questions for each of the 79 personality disorder criterions and raters are instructed to 
assign a “threshold” rating if there is sufficient evidence that the characteristic described 
in the criterion is pathological, persistent, and pervasive (First, et al., 1995).  The 
dimensional PD score can range from 0 to 158.  The Cluster A dimensional score ranges 
from 0 to 46; Cluster B has a range of 0 to 66; and, Cluster C can range from 0 to 46. 
Moreover, the SCID-II questionnaire was given to each participant at the 
screening and at the end of treatment.  The SCID-II questionnaire is a 119-item, self-
report personality assessment that can be used in conjunction with the SCID-II and 
provides some insight into the influence of depressive episode on over-reporting of 
personality pathology (First, et al., 1995).  The SCID-II questionnaire score can range 
from 0-119 as 1 point is scored for each endorsed item.  Elevated scores are indicative of 
higher levels of personality pathology.  Furthermore, 8 SCID-II assessments were 
videotaped and scored by trained graduate students to evaluate inter-rater reliability.  
The primary outcome measure for the proposed study is the BDI-II (Beck, Steer, 
& Brown, 1996), a widely used self-report measure for depression that includes 21 items, 
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each of which is scored from 0 to 3 to reflect the intensity of corresponding depressive 
symptoms.  The respondent's score is the sum of these item scores and can range from 0 
to 63.  The BDI–II and its predecessor, the BDI, have been the most widely used self-
report measures of outcome in research on cognitive therapy for depression (Beck, Steer, 
& Garbin, 1988).  Psychometric studies indicate that the BDI-II has high internal 
reliability, with an estimated coefficient alpha of .92 for psychiatric patients (Beck, Steer, 
& Brown, 1996). 
 The 17-item HRSD is a widely used clinician-rated scale that covers a set of 
affective, behavioral, and biological symptoms of depression, with scores ranging from 0 
to 52.  The HRSD has been found to have acceptable psychometric properties, with inter-
rater reliability coefficients ranging from .83 to .94 across different studies (Rabkin & 
Klein, 1987).  Moreover, the HRSD correlates relatively highly with the BDI-II, with 
studies showing a range of correlations from .68 to .72 (Beck, Steer, & Brown, 1996).  
The HRSD was given using the interview format developed by Williams (1988) and is 
included as a secondary outcome measure due to its widespread usage in the psychiatric 
literature.   
 As detailed in Karwoski (2006), adherence to TLC homework assignments were 
measured by asking the patients to record on Weekly Record Forms (Appendix A) each 
day the degree to which they are following the recommended lifestyle changes and a 
rating of their mood that day.  The Weekly Record Forms were developed by our 
research team and were modeled after the Diary Cards widely used in Dialectical 
Behavioral Therapy (DBT; Linehan, 1993).  The Weekly Record Forms begin by asking 
the patient to record whether they have taken the Omega-3 fish oil supplements, a 
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baseline measurement of sleep and exercise, and a rating of their mood on a Likert scale 
from 1 to 10.  As successive lifestyle changes were introduced, patients were asked to 
record their adherence to corresponding homework assignments.  
For hours of sleep, patients were given a score for compliance calibrated as the 
percentage of the targeted 8 hours of sleep obtained each night.  Hypersomnolent patients 
had their compliance rating reduced by a commensurate percentage for every hour above 
9 hours per night.  For bright light exposure, a patient was considered 100% compliant if 
he or she got 30 or more minutes per day.  Otherwise, compliance was rated as a 
percentage of the targeted 30 minutes each day and averaged across the weeks for which 
data is collected.  Likewise, patients were considered 100% compliant with the exercise 
requirement if they got 35 or more minutes of exercise three times a week.  Anything less 
was rated as a percentage of this target, and a weekly average was calculated.  Patients 
reported whether they had taken their omega-3s for the day, so adherence was measured 
by averaging the number of days that patients reported taking the full proscribed dosage.  
Pleasant activities, which are considered anti-ruminative, were measured as the 
percentage of days per week that patients reported engaging in at least one of them.  
Patients were asked to engage in at least one social activity each day.  Adherence to this 
TLC element was measured as the percentage of days per week that patients reported 
engaging in at least one social activity.  It should be noted that the ratings of patients who 
adhered to the TLC elements more than the amount proscribed by the protocol do not 
reflect the “extra” adherence.  That is, a patient that gets 30 minutes of bright light each 
day and a patient that gets 60 minutes of bright light each day are both considered 100% 
compliant.    
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 Weekly Record Forms were analyzed to determine the degree to which patients in 
TLC actually made the major lifestyle changes.  It should be noted that upon closer 
examination, the variable used to measure the sleep component in TLC was judged to be 
problematic.  The data collected for sleep adherence (i.e., the percentage of the targeted 8 
hours of sleep obtained each night) is closely aligned with depressive symptomatology.  
As both assessments of treatment response (BDI-II and HRSD) include items directly 
related to sleep, the amount of sleep a patient reports may be more of an artifact of their 
depression than an estimate of compliance to the proscribed 8 hours of sleep.  That is, it 
would be hard to make the theoretical argument that a patient who gets less sleep due to 
the severity of his or her depression is less “adherent” to the TLC protocol.  
Consequently, due to this significant conflation of the sleep adherence variable and 
depressive symptomatology, it was determined that it would be best to leave this variable 
out of the analyses involving adherence.   
Thus, estimates of adherence for 5 of the 6 components of TLC (i.e., omega-3 
consumption, bright light exposure, exercise, pleasant activities, and social support) were 
obtained by computing a mean for each of the 5 variables of the corresponding adherence 
data collected during the weeks that patients were asked to record them.  In addition, a 
weekly composite adherence score was computed for each participant by averaging the 5 
mean z-normed weekly adherence scores for each TLC element.  Moreover, a global 
adherence score was computed for each participant by averaging the mean, z-normed 
composite adherence scores for each of the 5 TLC elements.  Furthermore, although their 
data was included in all analyses, patients were considered “dropouts” if they missed 
more than 3 sessions or stated that they would no longer like to attend group.  If no 
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observation was documented at the end of treatment, data were carried forward from the 
last observation to serve as the outcome variable.   
Procedure 
 Participants were invited to join the first available group, typically beginning 
within a few weeks of the intake screen.  Each participant completed the BDI-II during 
the first five minutes of group each week.  Additionally, each participant was re-assessed 
on the HRSD by a graduate student rater at the fifth session, the ninth session, and the 
final twelfth session.  Raters were not explicitly told what treatment condition the patients 
were in.   
Description of Protocol 
 As described in Karwoski (2006), Therapeutic Lifestyle Change groups followed 
a detailed 12-session protocol, developed by the members of the TLC Research Group 
under the direction of Dr. Stephen Ilardi at the University of Kansas (Ilardi et al., 2005).  
Each part of the protocol was written by Dr. Ilardi or a graduate research assistant in the 
lab.  In addition, the TLC lab developed a set of patient handouts corresponding to each 
session of the group.  A brief description of the structure and content of the group 
sessions is provided in this section.  
 The first TLC session is the most psychoeducational in nature.  The group co-
leaders outline the evolutionary rationale behind the program, emphasizing ways in 
which our modern environment is different from the ancestral environment and why this 
is important for depression.  Co-leaders also conduct an exercise in which they describe 
the major areas of functioning affected by depression (mood, cognition, behavior, and 
physiology) and invite group members to share symptoms they have experienced.  The 
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group concludes with a discussion of the role of diet on neurological function and 
distribution of the Omega-3 fatty acid supplements (with instructions on how to take 
them).  Homework for the first session consists of taking the Omega-3 supplements with 
a multi-vitamin, beginning to record daily activities and mood on the weekly record form, 
and becoming aware of and monitoring when and how much they are ruminating. 
 Sessions 2 through 7 (and session 9) all follow the same basic format.  The first 
45 minutes of the session are spent reviewing homework from the week before.  
Homework assignments involve implementing a lifestyle change based on the 
psychoeducational topic for that week.  When patients report problems with adherence, 
group members and leaders work to find solutions to obstacles.  In the second part of 
each session, new material for that week is introduced.  In the second week, members 
learn how to use behavioral activation strategies to combat rumination.  In the third week, 
the concept of antidepressant exercise is introduced, and exercise consultants are present 
at the meeting to schedule each member’s first workout.  Each group member meets with 
an exercise consultant for three one-hour sessions in the three weeks following the 
exercise session to develop a workout plan and learn to monitor heart rate (i.e., to ensure 
that each workout is of aerobic intensity).  During the next four group sessions, members 
are taught to get daily bright light exposure, to enhance social connectedness, develop 
better sleep hygiene, and to address the corrosive effects of the modern social 
environment upon self-esteem.  Participants are either given a light box to use for the 
duration of the treatment or encouraged to use a light box that is available in Fraser Hall 
when the weather is not sunny. 
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 Sessions 8, 10, 11, and 12 are all devoted to review and relapse prevention. 
Session 11 takes place in the twelfth week of the program, and session 12 takes place the 
fifteenth week.  Spacing the final sessions out gives patients practice maintaining the 
lifestyle changes without the support of the group and co-therapists.  During these final 
sessions, patients learn the importance of continuing to adhere to the lifestyle changes, 
troubleshoot obstacles to adherence in advance, and assess which elements were 
particularly helpful for them in overcoming depression. 
 As detailed in Karwoski (2006), the introduction of the material follows a specific 
order.  Nutrition is the first major topic introduced, based on the rationale that taking a 
nutritional supplement and multivitamin is a relatively easy assignment that most patients 
should achieve success with.  Also in the first session patients are asked to notice when 
they are ruminating but not to initiate any intervention to stop its occurrence.  Again, this 
is a relatively easy assignment, and once patients notice what rumination is, they are 
often much more motivated to learn and implement behavioral strategies to combat it, 
which is the assignment for the second session.  Exercise is introduced in the third 
session, with the idea being that this is early enough that the therapists will have time to 
help patients get in a regular exercise routine, but late enough so that patients will have 
had several success experiences and feel confident in their ability to make this change.  
Light exposure is introduced next, in the fourth session, since it is a major change, and 
also a change that some patients see benefit from relatively quickly.  Socialization and 
sleep strategies are the last two major elements introduced because they are more easily 
modifiable in patients who have already begun the recovery process.  Esteem 
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maintenance and flow are introduced late in the protocol because they can be considered 
extensions of, respectively, socialization and behavioral activation. 
 Aside from the group meetings, the co-therapists also contact each member of the 
group by phone weekly.   Phone calls are targeted to last no longer than 15 minutes 
apiece, although there is not a strict limit.  There are several reasons for these phone calls. 
At the beginning of therapy, the phone calls are an important way to build rapport, 
address any concerns the patient might have hesitated to bring up in front of the rest of 
the group, and begin to get to know the patient on an individual basis.  As therapy 
progresses, the phone calls become much less important for the patients who are adhering 
well and seeing rapid symptom improvement, but for those who are struggling more, they 
become a way for the therapist to troubleshoot problems more thoroughly outside of the 
group context. 
Data Analyses 
Three principal hypotheses of the proposed study will be tested by means of 
regression analyses – specifically, that: (1) the presence of comorbid personality 
pathology is associated with less treatment adherence to TLC for depression; (2) the 
presence of comorbid personality pathology is associated with poorer treatment response 
to TLC for depression; and (3) treatment adherence to TLC is positively associated with 
treatment response.  Moreover, it has been established that pre-treatment depression 
severity is positively correlated with level of post-treatment depressive symptomatology 
(e.g., Croughan et al., 1988).  Thus, the importance of determining the extent to which 
TLC treatment response associated with co-occurring PD is due to the correlation 
between personality pathology and initial depression severity needs to be addressed 
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(Ilardi & Craighead, 1995).  Consequently, initial depression severity will serve as a 
covariate in each multiple regression analysis.   
Furthermore, the fourth hypothesis of the study postulates that adherence serves 
as a mediator for the effect of personality pathology on treatment response.  One can infer 
the existence of mediation indirectly from the 3 regression analyses conducted for each 
model (Baron & Kenny, 1986).  Nevertheless, even if the first three principal hypotheses 
are supported, it is possible that the indirect effect is still not significant.  Therefore, a 
macro designed to generate estimates for indirect effects in a mediator model will be 
utilized to more directly evaluate the mediational role of adherence on treatment response 
(Preacher & Hayes, 2007).  The macro employs a nonparametric bootstrapping procedure 
to generate a sampling distribution of the indirect effect of personality pathology on 
treatment outcome through adherence that does not involve making any distributional 
assumptions – a feat that can not be accomplished in a mediation test solely employing 
the three regression analyses of each model.  Preacher and Hayes (2004) note “the 
bootstrapping is accomplished by taking a large number of samples of size n (where n is 
the original sample size) from the data, sampling with replacement, and computing the 
indirect effect in each sample (p. 722).”  It has been suggested that this method 
effectively eludes the power problem presented by asymmetries and other forms of 
nonnormality in the sampling distribution of interest (Bollen & Steine, 1990).  In 
addition, Preacher and Hayes (2004) assert that the macro produces a test that is not 
based on large-samples theory; thus, it can be applied to small samples with more 
confidence.  95% bias-corrected and accelerated confidence intervals will be generated to 
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determine if adherence significantly mediates the effect of personality pathology on TLC 
treatment response. 
The four principal hypotheses were tested in each of 20 sets of models.  The 20 
sets of models were constructed by interchanging the 5 personality pathology variables, 
interchanging the 6 adherence variables, and interchanging the 2 treatment outcome 
measures.  Specifically, one series of 10 sets of models was formed according to a 5 
personality pathology variables (dichotomous PD, dimensional PD, Cluster A 
dimensional, Cluster B dimensional, and Cluster C dimensional) X 1 adherence variable 
(global) X 2 treatment outcome variables (posttreatment BDI-II and posttreatment 
HRSD) framework; and, the second series was constructed in a 1 personality pathology 
variable (dimensional PD) X 5 adherence variables (TLC components – omega-3, bright 
light, exercise, pleasant activities, and social support) X 2 treatment outcome variables 
(posttreatment BDI-II and posttreatment HRSD) framework.  The testing of each model 
consisted of three regression analyses, in which initial depression severity served as the 
covariate, and a mediation test conducted with the aforementioned macro (Preacher & 
Hayes, 2007).   
The global adherence variable served as the adherence variable in the first 10 sets 
of models.  This variable was utilized as it gives the best sense of overall adherence to 
TLC treatment.  The investigation of effects of adherence to the components of TLC was 
conducted with the testing of the second series of 10 additional sets of models.  As 
relevant information is often lost with the employment of a categorical variable (Ilardi et 
al., 1997; Mulder, 2002), the dimensional PD score served as the personality pathology 
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variable in each set of models.  This variable was employed because it provides the best 
sense of overall personality pathology.   
Furthermore, a Fisher’s Exact Test was conducted to evaluate between-group 
differences in treatment response, defined as at least a 50% reduction of depressive 
symptomatology on the BDI-II or HRSD.  In addition, inter-rater reliability of the SCID-
II personality pathology assessment and internal reliability of the Weekly Record Form 
were also assessed.  
RESULTS 
Characteristics of Patients 
Sixty-eight patients met study inclusion criteria.  Ages of patients ranged from 18-
62 years with an average of 43.4.  Twenty (29.4%) of the patients that entered TLC were 
male and thirty-three (48.5%) were married (Table 1).  Also, the mean number of years of 
education was 16.0.    In addition, at intake, fifteen patients (22.1%) were in 
psychotherapy and forty (58.8%) were on medication.  Moreover, the mean baseline  
BDI-II score (i.e., at intake) was 28.9 with a SD of 8.9.  Also, the mean baseline HRSD 
score, the study’s secondary depression measure, was 19.3 with a SD of 5.7.  
 
Table 1.  
Characteristics of Participants According to Axis II Personality Disorder Diagnosis. 
 
 Age 
Mean 
(SD) 
Male 
No., 
(%) 
Married
No., (%) 
Education
Mean, 
(SD) 
In 
therapy 
at 
intake 
No., 
(%) 
On 
medication 
at intake 
No., (%) 
Baseline 
BDI-II 
Mean, (SD)
Baseline 
HRSD 
Mean, (SD)
No PD 
(N=30) 
44.4 
(11.2) 
8 
(26.7) 
13 
(43.3) 
16.4 
 (2.1) 
8 
(26.7) 
20 
(66.7) 
25.8** 
(9.5) 
17.9a 
(6.0) 
PD 42.7 12 20 15.7b 7 20 31.4** 20.4 
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(N=38) (12.0) (31.6) (54.1) (2.5) (18.4) (52.6) (7.7) (5.3) 
Total 
(N=68) 
43.4 
(11.6) 
20 
(29.4) 
33 
(48.5) 
16.0 
(2.6) 
15 
(22.1) 
40 
(58.8) 
28.9 
(8.9) 
19.3 
(5.7) 
 
** p < .01 
a Data for this variable is missing for 1 participant. 
b Data for this variable is missing for 2 participants. 
 
Fifty-six percent (N=38) of patients were diagnosed with at least one Axis II 
personality disorder (PD) according to the SCID-II.  The mean of the dimensional PD 
variable for the study sample (N=68), which ranged from 0 to 158, was 29.3 with a 
standard deviation (SD) of 16.0.  Twelve patients in the study (17.6%) met diagnostic 
criteria for at least one Cluster A personality disorder.  The mean of the Cluster A 
dimensional variable (N=68), which ranged from 0-46, was 7.4 with a SD of 5.6.  Also, 
five patients (7.4%) received a diagnosis of at least one Cluster B PD; and, the mean of 
the Cluster B continuous variable, which ranged from 0-66, was 7.9 with a SD of 7.1.  In 
addition, thirty-four patients (50%) were diagnosed with at least one Cluster C PD.  The 
mean of the Cluster C dimensional variable, which ranged from 0-46, was 14.3 with a SD 
of 7.2.  Furthermore, twenty-three patients (60.5%) in the PD group (N=38) were 
diagnosed with one Axis II PD, eight (21.1%) were diagnosed with 2 PD’s, and 7 
(18.4%) met diagnostic criteria for 3 or more PD’s.  
The PD group (i.e., patients diagnosed with at least one Axis II PD) (N=38) and 
the group of patients without an Axis II PD diagnosis (NPD) (N=30) were comparable on 
demographic variables (Table 1).  Fisher’s Exact Tests revealed that the PD and NPD 
groups did not differ in terms of sex (p = .79), proportion of patients in therapy at intake 
(p = .56), and proportion of patients on medication at intake (p = .32).  Moreover, 
independent samples t-tests revealed that the two groups did not differ in terms of age 
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(t(66) = .591, p = .56) and level of education (t(64) = 1.21, p = .23).  Although the 
difference between baseline HRSD scores among groups failed to reach the threshold of 
significance (t(65) = 1.79, p = .08; Axis II mean = 20.42; non-Axis II mean = 17.93), as 
expected, patients in the PD group scored significantly higher on the study’s primary 
baseline depression measure, BDI-II (t(66) = -2.72, p < .01; Axis II mean = 31.42; non-
Axis II mean = 25.77).  
Reliability 
 An internal consistency estimate of reliability of the TLC Weekly Record Form 
(WRF) was computed on the basis of reported adherence data from session 10, following 
a week of treatment in which no new TLC element was introduced.  The internal 
reliability test of the WRF yielded a Cronbach’s alpha of .52, indicating that the WRF has 
a moderate amount of internal consistency.  That is, there is reason to believe that the 
items on the WRF tap into an underlying adherence construct. 
 A test of inter-rater reliability was conducted using data collected from eight 
videotaped SCID-II assessments that were scored by trained graduate students on the 
TLC research team.  A two-way random effects model yielded an intraclass correlation of 
.97, indicating very strong inter-rater reliability for the SCID-II personality pathology 
assessment. 
 A paired samples t-test was conducted to compare the scores of the self-report 
SCID-II questionnaire that was given at baseline and at posttreatment.  The t-test 
indicates that patients obtained a significantly higher score on the SCID-II questionnaire 
given at baseline than the one given post-treatment (t(44) = 4.3, p < .01 ).  Consistent 
with the literature (Mulder, 2002; Zimmerman, 1994), the t-test result suggests that the 
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presence of comorbid depression is associated with potential over-reporting of 
personality pathology on self-report measures – a problem that is largely addressed in the 
present study by means of employing a semi-structured interview (SCID-II) as the 
principal Axis II measure (Spitzer, Williams, Gibbon, & First, 1990). 
 
Effect of Personality Pathology on Adherence to TLC Treatment 
 PD and NPD groups were comparable on adherence to components of TLC 
(Table 2).  Independent samples t-tests indicate that the two groups do not significantly 
differ in terms of adherence to omega-3 (t(66) = -.64, p = .52), bright light exposure 
(t(63) = .338, p = .74), exercise (t(66) = .565, p = .57), pleasant activities (t(65) = .797, p 
= .43), and social activity (t(48) = 1.33, p = .19).  In addition, a Fisher’s Exact Test (p = 
.49) indicates that the rate of dropout among the PD and NPD groups is not significantly 
different.  Moreover, Figure 1 shows that the PD and NPD groups exhibit a similar 
pattern of adherence throughout treatment.  An independent samples t-test also indicated 
that there was no significant difference among the PD and NPD groups with regard to 
their global adherence to the TLC treatment (t(66) = .80, p = .43). 
Table 2. 
 
Degree of Adherence to TLC Components. 
 
 Omega 3 
%, (SD) 
Bright 
Light 
%, 
(SD) 
Exercise 
%, (SD) 
Pleasant 
Activity 
%, (SD) 
Social 
Support 
%, (SD) 
Globala 
(overall) 
Mean, 
(SD) 
Dropoutb
No., % 
No PD 
(N=30) 
88.8 
(17.7) 
66.0 c 
(17.3) 
66.0 
(22.7) 
69.6 d 
(20.0) 
60.7e 
(22.4) 
.060 
(.59) 
3 
(10) 
PD 
(N=38) 
90.1 
(8.8) 
64.3f 
(22.1) 
62.9 
(23.0) 
65.9 
(17.7) 
51.7 g 
(24.1) 
-.05 
(.52) 
7 
(18.4) 
Total 
(N=68) 
90.0 
(13.4) 
65.0 
(20.0) 
64.2 
(22.8) 
67.5 
(18.7) 
55.3 
(23.6) 
0.0 
(.55) 
10 
(14.7) 
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a Calculated as the mean of the z-scored component adherence variables. 
b Missed more than 3 sessions. 
c Data for this variable is missing for 2 participants. 
d Data for this variable is missing for 1 participant. 
e Data for this variable was not collected for 10 patients (i.e., the revised Weekly Record  
Form had not been introduced during treatment for these participants). 
f Data for this variable is missing for 1 participant. 
g Data for this variable was not collected for 8 patients (i.e., the revised Weekly Record  
Form had not been introduced during treatment for these participants). 
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Figure 1.  Global adherence by session. 
 
Linear regression analyses were conducted to predict global adherence to TLC 
treatment from the dichotomous PD variable with pretreatment BDI-II and pretreatment 
HRSD (Table 3) serving as covariates.  The regression results (p = .36 and p = .17, 
respectively) suggest that a diagnosis of at least one Axis II PD does not significantly 
predict overall adherence to TLC treatment after controlling for initial depression 
severity. 
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Table 3. 
 
Summary of the Linear Regression Analyses for Personality Pathology predicting Global 
Adherence with Initial Depression Severity serving as a Covariate. 
 
Variable B SE B β 
Pretreatment BDI-II .004 .008 .07 
Dichotomous PD -.13 .14 -.12 
Pretreatment HRSD .03 .01 .30 
Dichotomous PD -.19 .13 -.171 
Pretreatment BDI-II .002 .008 .031 
Dimensional PD .000 .005 -.002 
Pretreatment HRSD .03 .01 .28 
Dimensional PD -.003 .004 -.08 
Pretreatment BDI-II .002 .008 .03 
Cluster A .001 .01 .006 
Pretreatment HRSD .03 .01 .26 
Cluster A -.002 .01 -.021 
Pretreatment BDI-II .002 .008 .04 
Cluster B -.001 .01 -.02 
Pretreatment HRSD .03 .01 .30 
Cluster B -.008 .01 -.106 
Pretreatment BDI-II .002 .008 .028 
Cluster C .001 .01 .01 
Pretreatment HRSD .03 .01 .28 
Cluster C -.005 .01 -.06 
 
  
 The hypotheses that dimensional PD predicts global adherence to TLC treatment 
with pretreatment BDI-II and pretreatment HRSD (Table 3) serving as covariates were 
also evaluated.  The results of the regression analyses (p = .99 and p = .53, respectively) 
suggest that dimensional PD score does not significantly predict overall adherence to 
TLC after controlling for initial depression severity.  
 Linear regression analyses were also carried out to predict global adherence to 
TLC treatment from Cluster dimensional scores with pretreatment BDI-II and 
pretreatment HRSD serving as covariates.  The results of the regression analyses for 
Cluster A (p = .96 and p = .86, with pretreatment BDI-II and pretreatment HRSD serving 
 39
as covariates, respectively), Cluster B (p = .89 and p = .41), and Cluster C (p = .94 and p 
= .62) (Table 3) suggest that one’s Axis II cluster pathology does not significantly predict 
his or her overall adherence to TLC after controlling for initial depression severity. 
   Linear regression analyses were also conducted to predict adherence to TLC 
components from dimensional PD with pretreatment BDI-II and pretreatment HRSD 
serving as covariates.  The regression results for omega-3 consumption (p = .87 and p = 
.76, with pretreatment BDI-II and pretreatment HRSD serving as covariates, 
respectively), bright light (p = .55 and p =.91), exercise (p = .86 and p = .68),  pleasant 
activities (p = .58 and p = .50), and social support (p = .81 and p = .57) (Table 4) suggest 
that dimensional PD score does not significantly predict adherence to TLC components 
after controlling for initial depression severity. 
 
Table 4. 
 
Summary of the Linear Regression Analyses for Dimensional PD predicting Adherence to 
TLC Components with Initial Depression Severity serving as a Covariate. 
 
 
TLC 
Component 
Variable B SE B β 
Omega-3 Pretreatment BDI-II .01 .02 .09 
 Dimensional PD .001 .008 .02 
 Pretreatment HRSD .01 .02 .06 
 Dimensional PD .003 .008 .04 
Bright Light Pretreatment BDI-II -.008 .02 -.07 
 Dimensional PD .005 .01 .09 
 Pretreatment HRSD .04 .02 .21 
 Dimensional PD -.001 .008 -.01 
Exercise Pretreatment BDI-II -.002 .02 -.02 
 Dimensional PD -.002 .008 -.02 
 Pretreatment HRSD .02 .02 .11 
 Dimensional PD -.003 .008 -.05 
Pleasant Activity Pretreatment BDI-II .01 .02 .11 
 Dimensional PD -.005 .008 -.08 
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 Pretreatment HRSD .02 .02 .13 
 Dimensional PD -.005 .008 -.088 
Social Activity Pretreatment BDI-II -.01 .02 -.13 
 Dimensional PD .002 .01 .04 
 Pretreatment HRSD .03 .03 .16 
 Dimensional PD -.006 .01 -.09 
 
 
  
Effect of Personality Pathology on TLC Treatment Outcome  
Depressive symptomatology was greatly reduced for both the PD and NPD 
groups (Figure 2; Table 5).  23 patients out of 30 (77%) in the NPD group achieved a 
clinically significant treatment response, defined as a reduction of at least 50% in 
depressive symptomatology from baseline, vis-à-vis the BDI-II.  26 patients out of 38 
(68%) in the PD group achieved a clinically significant treatment response.  A Fisher’s 
Exact Test was conducted to compare the rate of recovery among the two groups.  The 
results of the test indicate that the PD and NPD groups do not differ significantly on rate 
of recovery (p = .59).  Furthermore, 19 patients out of 29 (66%) in the NPD group 
achieved at least a 50% reduction in depressive symptomatology according to the HRSD 
compared to 19 patients out of 38 (50%) in the PD group.  A Fisher’s Exact Test 
indicates that this difference is also not significant (p = .33).   
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Figure 2.  BDI-II scores by session for PD and NPD groups. 
 
Table 5.  
 
Mean Baseline and Post-Treatment BDI-II and HRSD Scores. 
 
 No PD (N=30) PD (N=38) 
 MEAN (SD) MEAN (SD) 
BDI-II   
Baseline 25.8 (9.5) 31.4 (7.7) 
Post-Treatment 9.0 (7.2) 11.6 (11.1) 
HRSD   
Baseline 17.9 (6.0)a 20.4 (5.3) 
Post-Treatment 8.0 (6.7) 10.8 (7.8) 
 
a Data for this variable is missing for 1 participant. 
 
 
Linear regression analyses were conducted to predict treatment response from the 
dichotomous PD variable with pretreatment BDI-II (Table 6) and pretreatment HRSD 
(Table 7) serving as corresponding covariates.  The regression results (p = .50 and p = 
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.15, respectively) suggest that a diagnosis of at least one Axis II PD does not significantly 
predict treatment outcome after controlling for initial depression severity. 
 
Table 6. 
 
Summary of the Linear Regression Analysis for Dichotomous PD predicting 
Posttreatment BDI-II with Pretreatment BDI-II serving as a Covariate. 
 
 
Variable B SE B β 
Pretreatment BDI-II .16 .14 .15 
Dichotomous PD 1.7 2.5 .09 
 
 
  
Table 7. 
 
Summary of the Linear Regression Analysis for Dichotomous PD predicting 
Posttreatment HRSD with Pretreatment HRSD serving as a Covariate. 
 
 
Variable B SE B β 
Pretreatment HRSD -.13 .16 -.11 
Dichotomous PD 2.7 1.8 .20 
 
 
 The hypotheses that dimensional PD is predictive of treatment response, with 
pretreatment BDI-II (Table 8) and pretreatment HRSD (Table 9) serving as 
corresponding covariates, were examined in linear regression frameworks.  The results of 
the regression analyses (p = .18 and p = .13 respectively) suggest that dimensional PD 
score does not significantly predict treatment outcome after controlling for initial 
depression severity. 
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Table 8. 
 
Summary of the Linear Regression Analysis for Dimensional PD predicting 
Posttreatment BDI-II with Pretreatment BDI-II serving as a Covariate. 
 
 
Variable B SE B β 
Pretreatment BDI-II .11 .14 .10 
Dimensional PD .11 .08 .18 
 
  
Table 9. 
 
Summary of the Linear Regression Analysis for Dimensional PD predicting 
Posttreatment HRSD with Pretreatment HRSD serving as a Covariate. 
 
 
Variable B SE B β 
Pretreatment HRSD -.13 .16 -.11 
Dimensional PD .09 .06 .21 
 
In addition, linear regression analyses were carried out to predict treatment 
response from the Cluster A variable with pretreatment BDI-II (Table 10) and 
pretreatment HRSD (Table 11) serving as corresponding covariates.  The regression 
results (p = .02 and p = .01, respectively) suggest that higher Cluster A pathology 
predicts poorer treatment outcome after controlling for initial depression severity.  Figure 
3 illustrates the patterns of response of Cluster A-disordered patients and patients without 
a PD diagnosis.   
 
Table 10. 
 
Summary of the Linear Regression Analysis for Cluster A predicting Posttreatment BDI-
II with Pretreatment BDI-II serving as a Covariate. 
 
Variable B SE B β 
Pretreatment BDI-II .09 .13 .09 
Cluster A * .53 .21 .31 
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* p < .05 
  
 
 
Table 11. 
 
Summary of the Linear Regression Analysis for Cluster A predicting Posttreatment 
HRSD with Pretreatment HRSD serving as a Covariate. 
 
Variable B SE B β 
Pretreatment HRSD -.10 .15 -.08 
Cluster A** .41 .15 .35 
 
** p ≤ .01 
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Figure 3. BDI-II scores by session for patients above and below the median on 
dimensional Cluster A score. 
 
Linear regression analyses were also performed to predict treatment response 
from the Cluster B variable with pretreatment BDI-II (Table 12) and pretreatment HRSD 
(Table 13) serving as corresponding covariates.  The regression results (p = .01 and p = 
.19, respectively) suggest that higher Cluster B pathology predicts poorer treatment 
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response on the primary treatment outcome measure, BDI-II, after controlling for 
baseline BDI-II score.  Moreover, Figure 4 shows that Cluster B-disordered patients and 
the NPD group exhibit contrasting patterns of response throughout treatment.   
 
Table 12. 
 
Summary of the Linear Regression Analysis for Cluster B predicting Posttreatment BDI-
II with Pretreatment BDI-II serving as a Covariate. 
 
Variable B SE B β 
Pretreatment BDI-II .05 .14 .05 
Cluster B** .43 .17 .32 
 
** p ≤ .01 
  
Table 13. 
 
Summary of the Linear Regression Analysis for Cluster B predicting Posttreatment 
HRSD with Pretreatment HRSD serving as a Covariate. 
 
Variable B SE B β 
Pretreatment HRSD -.13 .17 -.11 
Cluster B .22 .17 .18 
 
 
 
0
5
10
15
20
25
30
35
40
BS
L S1 S2 S3 S4 S5 S6 S7 S8 S9 S1
0
S1
1
S1
2
TLC Session
B
D
I-I
I Below the Median
Above the Median
 
 
 46
Figure 4. BDI-II scores by session for patients above and below the median on 
dimensional Cluster B score. 
 
 
The hypotheses that the Cluster C variable is predictive of treatment response 
with pretreatment BDI-II (Table 14) and pretreatment HRSD (Table 15) serving as 
corresponding covariates were tested in linear regression analyses.  The regression results 
(p = .22 and p = .72, respectively) suggest that Cluster C pathology does not significantly 
predict treatment outcome after controlling for initial depression severity.  It is evident 
from Figure 5 that Cluster C-disordered patients respond similarly compared to patients 
without an Axis II PD diagnosis. 
 
Table 14. 
 
Summary of the Linear Regression Analysis for Cluster C predicting Posttreatment BDI-
II with Pretreatment BDI-II serving as a Covariate. 
 
Variable B SE B β 
Pretreatment BDI-II .24 .14 .22 
Cluster C -.21 .17 -.16 
 
 
 
Table 15. 
 
Summary of the Linear Regression Analysis for Cluster C predicting Posttreatment 
HRSD with Pretreatment HRSD serving as a Covariate. 
 
Variable B SE B β 
Pretreatment HRSD -.09 .17 -.08 
Cluster C .05 .13 .05 
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Figure 5. BDI-II scores by session for Cluster C-disordered patients and patients without 
an Axis II PD. 
 
 
Effect of Adherence on TLC Treatment Outcome 
 
The third principal hypothesis – that adherence to TLC predicts TLC treatment 
response – was also tested with a number of linear regression analyses, with initial 
depression severity and personality pathology variables serving as covariates.  Linear 
regression analyses were conducted to predict treatment response from the global 
adherence variable with dichotomous PD serving as a covariate and pretreatment BDI-II 
(Table 16) and pretreatment HRSD (Table 17) serving as corresponding covariates.  The 
regression results (p = .047 and p = .59, respectively) suggest that higher overall 
adherence to TLC predicts better treatment response on the primary treatment outcome 
measure, BDI-II, after controlling for initial depression severity and the dichotomous 
personality disorder variable. 
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Table 16. 
 
Summary of the Linear Regression Analysis for Global Adherence predicting 
Posttreatment BDI-II with Pretreatment BDI-II and Dichotomous PD serving as 
Covariates. 
 
Variable B SE B β 
Pretreatment BDI-II .18 .14 .16 
Dichotomous PD 1.1 2.4 .06 
Global Adherence* -4.2 2.10 -.24 
 
* p < .05 
 
  
 
Table 17. 
 
Summary of the Linear Regression Analysis for Global Adherence predicting 
Posttreatment HRSD with Pretreatment HRSD and Dichotomous PD serving as 
Covariates. 
 
Variable B SE B β 
Pretreatment HRSD -.11 .17 -.09 
Dichotomous PD 2.5 1.9 .19 
Global Adherence -.93 1.7 -.07 
 
 
The hypotheses that global adherence is predictive of TLC treatment outcome 
were evaluated in linear regression frameworks with dimensional PD serving as a 
covariate and pretreatment BDI-II (Table 18) and pretreatment HRSD (Table 19) serving 
as corresponding covariates.  The results of the regression analyses (p = .04 and p = .15, 
respectively) suggest that higher overall adherence to TLC predicts enhanced treatment 
response vis-à-vis the primary treatment outcome measure, BDI-II, after controlling for 
initial depression severity and dimensional PD. 
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Table 18. 
 
Summary of the Linear Regression Analysis for Global Adherence predicting 
Posttreatment BDI-II with Pretreatment BDI-II and Dimensional PD serving as 
Covariates. 
 
Variable B SE B β 
Pretreatment BDI-II .12 .14 .11 
Dimensional PD .11 .08 .18 
Global Adherence* -4.4 2.1 -.25 
 
* p < .05 
  
 
Table 19. 
 
Summary of the Linear Regression Analysis for Global Adherence predicting 
Posttreatment HRSD with Pretreatment HRSD and Dimensional PD serving as 
Covariates. 
 
Variable B SE B β 
Pretreatment HRSD -.12 .17 -.10 
Dimensional PD .09 .06 .20 
Global Adherence -1.14 1.7 -.09 
 
Linear regression analyses were also carried out to predict treatment response 
from the global adherence variable with each Axis II cluster serving as a covariate and 
pretreatment BDI-II and pretreatment HRSD serving as corresponding covariates.  The 
regression results controlling for Cluster A (p = .03 and p = .49, with pretreatment BDI-II 
and pretreatment HRSD serving as covariates, respectively) (Table 20 & 21), Cluster B 
(p = .04 and p = .47) (Table 22 & 23), and Cluster C (p = .04 and p = .48) (Table 24 & 
25) suggest that higher overall adherence to TLC predicts better treatment response on 
the primary treatment outcome measure, BDI-II, after controlling for initial depression 
severity and Axis II cluster pathology. 
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Table 20. 
 
Summary of the Linear Regression Analysis for Global Adherence predicting 
Posttreatment BDI-II with Pretreatment BDI-II and Cluster A serving as Covariates. 
 
Variable B SE B β 
Pretreatment BDI-II .10 .13 .09 
Cluster A .53 .20 .31 
Global Adherence* -4.4 2.0 -.25 
 
* p < .05 
  
 
Table 21. 
 
Summary of the Linear Regression Analysis for Global Adherence predicting 
Posttreatment HRSD with Pretreatment HRSD and Cluster A serving as Covariates. 
 
Variable B SE B β 
Pretreatment HRSD -.08 .16 -.07 
Cluster A .41 .15 .35 
Global Adherence -1.13 1.63 -.09 
 
 
 
 
Table 22. 
 
Summary of the Linear Regression Analysis for Global Adherence predicting 
Posttreatment BDI-II with Pretreatment BDI-II and Cluster B serving as Covariates. 
 
Variable B SE B β 
Pretreatment BDI-II .06 .13 .06 
Cluster B .43 .17 .32 
Global Adherence* -4.3 2.0 -.24 
 
*p < .05 
  
Table 23. 
 
Summary of the Linear Regression Analysis for Global Adherence predicting 
Posttreatment HRSD with Pretreatment HRSD and Cluster B serving as Covariates. 
 
Variable B SE B β 
Pretreatment HRSD -.11 .17 -.09 
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Cluster B .22 .17 .18 
Global Adherence -1.2 1.7 -.10 
 
Table 24. 
 
Summary of the Linear Regression Analysis for Global Adherence predicting 
Posttreatment BDI-II with Pretreatment BDI-II and Cluster C serving as Covariates. 
 
 
Variable B SE B β 
Pretreatment BDI-II .25 .13 .23 
Cluster C -.21 .17 -.16 
Global Adherence* -4.34 2.06 -.25 
 
p < .05 
 
 
Table 25. 
 
Summary of the Linear Regression Analysis for Global Adherence predicting 
Posttreatment HRSD with Pretreatment HRSD and Cluster C serving as Covariates. 
 
Variable B SE B β 
Pretreatment HRSD -.07 .17 -.06 
Cluster C .04 .13 .04 
Global Adherence -1.24 1.74 -.10 
 
Also, the hypotheses that adherence to each TLC component is predictive of TLC 
treatment outcome were evaluated in linear regression frameworks with dimensional PD 
serving as a covariate and pretreatment BDI-II and pretreatment HRSD serving as 
corresponding covariates.  The results of the regression analyses for Omega-3 
consumption (p = .68 and p = .61, with pretreatment BDI-II and pretreatment HRSD 
serving as covariates, respectively) (Table 26 & 27), bright light (p = .34 and p = .78) 
(Table 28 & 29), pleasant activities (p = .76 and p = .65) (Table 30 & 31), and social 
support (p = .53. and p = .55) (Table 32 & 33) suggest that specific adherence to these 
four components of TLC does not significantly predict treatment outcome after 
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controlling for initial depression severity and dimensional PD.  However, the regression 
results for the exercise component (p = .003 and p = .38, respectively) (Table 34 & 35) 
suggest that higher adherence to the exercise component of TLC predicts significantly 
better treatment response on the primary treatment outcome measure, BDI-II, after 
controlling for initial depression severity and dimensional PD. 
Table 26. 
 
Summary of the Linear Regression Analysis for adherence to Omega-3 component 
predicting Posttreatment BDI-II with Pretreatment BDI-II and Dimensional PD serving 
as Covariates. 
 
Variable B SE B β 
Pretreatment BDI-II .12 .14 .11 
Dimensional PD .11 .08 .18 
Omega-3 -.49 1.17 -.05 
 
  
 
Table 27. 
 
Summary of the Linear Regression Analysis for Omega-3 component predicting 
Posttreatment HRSD with Pretreatment HRSD and Dimensional PD serving as a 
Covariate. 
 
Variable B SE B β 
Pretreatment HRSD -.13 .17 -.11 
Dimensional PD .09 .06 .22 
Omega-3 -.44 .85 -.07 
 
 
Table 28. 
 
Summary of the Linear Regression Analysis for adherence to Bright Light component 
predicting Posttreatment BDI-II with Pretreatment BDI-II and Dimensional PD serving 
as Covariates. 
 
Variable B SE B β 
Pretreatment BDI-II .09 .15 .08 
Dimensional PD .14 .08 .23 
Bright Light -1.13 1.19 -.12 
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Table 29. 
 
Summary of the Linear Regression Analysis for Bright Light component predicting 
Posttreatment HRSD with Pretreatment HRSD and Dimensional PD serving as a 
Covariate. 
 
Variable B SE B β 
Pretreatment HRSD -.13 .17 -.11 
Dimensional PD .09 .06 .21 
Bright Light -.26 .91 -.04 
 
 
 
Table 30. 
 
Summary of the Linear Regression Analysis for adherence to Pleasant Activities 
component predicting Posttreatment BDI-II with Pretreatment BDI-II and Dimensional 
PD serving as Covariates. 
 
 
Variable B SE B β 
Pretreatment BDI-II .13 .14 .12 
Dimensional PD .11 .08 .19 
Pleasant Activites -.37 1.17 -.04 
 
  
 
Table 31. 
 
Summary of the Linear Regression Analysis for Pleasant Activites component predicting 
Posttreatment HRSD with Pretreatment HRSD and Dimensional PD serving as a 
Covariate. 
 
Variable B SE B β 
Pretreatment HRSD -.14 .17 -.12 
Dimensional PD .09 .06 .21 
Pleasant Activites .41 .91 .06 
 
 
 
Table 32. 
 
Summary of the Linear Regression Analysis for adherence to Social Activities component 
predicting Posttreatment BDI-II with Pretreatment BDI-II and Dimensional PD serving 
as Covariates. 
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Variable B SE B β 
Pretreatment BDI-II .13 .15 .13 
Dimensional PD .19 .09 .31 
Social Activities -.84 1.32 -.09 
 
  
 
Table 33. 
 
Summary of the Linear Regression Analysis for Social Activities component predicting 
Posttreatment HRSD with Pretreatment HRSD and Dimensional PD serving as a 
Covariate. 
 
Variable B SE B β 
Pretreatment HRSD -.29 .20 -.22 
Dimensional PD .13 .07 .30 
Social Activities -.60 1.00 -.09 
 
 
 
 
Table 34. 
 
Summary of the Linear Regression Analysis for adherence to Exercise component 
predicting Posttreatment BDI-II with Pretreatment BDI-II and Dimensional PD serving 
as Covariates. 
 
Variable B SE B β 
Pretreatment BDI-II .11 .13 .01 
Dimensional PD .10 .07 .17 
Exercise** -3.30 1.09 -.34 
 
** p < .01 
  
 
 
Table 35. 
 
Summary of the Linear Regression Analysis for Exercise component predicting 
Posttreatment HRSD with Pretreatment HRSD and Dimensional PD serving as a 
Covariate. 
 
Variable B SE B β 
Pretreatment HRSD -.14 .17 -.12 
Dimensional PD .09 .06 .20 
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Exercise -.85 .97 -.12 
 
 
Mediation Tests 
The linear regression analyses used to test the first three principal hypotheses of 
the study (i.e., (1) the presence of comorbid personality pathology will be associated with 
reduced treatment adherence to TLC for depression; (2) the presence of comorbid 
personality pathology will be associated with poorer treatment response to TLC for 
depression; and (3) treatment adherence to TLC will be associated with treatment 
response vis-à-vis reduction in depressive symptomatology) combine to form a type of 
mediation test (Baron & Kenny, 1986).  However, a macro (Preacher & Hayes, 2007) 
designed to generate estimates for indirect effects in a mediator model was used as a 
more thorough test of mediation.  The macro employed 5,000 bootstrap resamples to 
generate a sampling distribution of the indirect effect of personality pathology on 
treatment outcome through adherence that does not involve making any distributional 
assumptions.  Moreover, 95% bias-corrected and accelerated confidence intervals were 
generated to determine if adherence significantly mediates the effect of personality 
pathology on TLC treatment response. 
A macro was run for each of the 20 sets of models tested.  Each resulting 
confidence interval bracketed the value 0.0 (Table 36), consistent with the hypothesis that 
adherence does not mediate the effect of personality pathology on treatment outcome.  
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 Table 36.  
 
Macroa test of Adherence Mediating the effect of Axis II Personality Pathology on 
Treatment Outcome.  
 
Mediator 
(adherence) 
Axis II  Treatment 
Outcome 
CIb – Lower 
Bound 
CIb – Upper 
Bound 
Global Dichot. PD BDI-II -.720 2.365 
Global Dichot. PD HRSD -.412 1.424 
Global Dimen. PD BDI-II -.055 .048 
Global Dimen. PD HRSD -.009 .035 
Global Cluster A BDI-II -.144 .106 
Global Cluster A HRSD -.034 .073 
Global Cluster B BDI-II -.099 .136 
Global Cluster B HRSD -.019 .087 
Global Cluster C BDI-II -.125 .093 
Global Cluster C HRSD -.025 .068 
Omega-3 Dimen. PD BDI-II -.018 .027 
Omega-3 Dimen. PD HRSD -.016 .011 
Bright Light Dimen. PD BDI-II -.066 .012 
Bright Light Dimen. PD HRSD -.017 .023 
Exercise Dimen. PD BDI-II -.046 .066 
Exercise Dimen. PD HRSD -.008 .035 
Pleasant Activ. Dimen. PD BDI-II -.012 .038 
Pleasant Activ. Dimen. PD HRSD -.039 .008 
Social Support Dimen. PD BDI-II -.041 .019 
Social Support Dimen. PD HRSD -.009 .037 
 
a Designed by Preacher & Hayes (2007) – using 5000 bootstrap resamples. 
b Confidence Interval – 95% bias-corrected and accelerated.  
 
DISCUSSION 
Effect of Personality Pathology on Adherence to TLC Treatment 
 Based on existing empirical literature documenting poor adherence associated 
with Axis II pathology (Cahalane, 1997; Herbeck et al., 2005; Sajtovic et al., 2004), 
patients with elevated levels of personality pathology were expected to exhibit less 
adherence to the TLC protocol in the present study.  Contrary to expectations, however, 
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no significant association between Axis II pathology and treatment adherence was 
observed.  This finding suggests that the characterological difficulties associated with 
diagnosed PD (e.g., excessive emotionality, deficits in interpersonal and occupational 
functioning, etc.) do not substantially impede patient adherence to the TLC protocol.   
Although this is a somewhat surprising result, it is possible that certain features of 
TLC facilitate adherence among personality-disordered patients.  For example, there is 
evidence that personality-disordered individuals respond better to more structured 
treatments with clearly defined goals in comparison with less-focused, insight-oriented 
interventions (Hirani, 2007; Saulsman et al., 2006; Van den Hout et al., 2006).  Thus, the 
structured nature of TLC – a protocol that emphasizes the adoption of concrete 
behavioral lifestyle changes – may serve to enhance compliance in individuals with 
personality pathology.  Also, the group format of TLC, which provides for implicit 
support and accountability between group members, may serve to facilitate adherence.  
Furthermore, the protocol’s provision of weekly therapist “coaching calls” may also 
increase patient accountability and provide enhanced motivation for compliance. 
 In addition, the method of enrollment of study participants may have resulted in a 
more highly motivated sample of personality-disordered individuals than is typically 
observed in the published treatment outcome literature.  Specifically, the present study 
was given widespread, favorable coverage by the local news media in the immediate 
catchment area, and was typically described as a “holistic” approach to the treatment of 
depression.  Moreover, numerous study participants commented (anecdotally) that they 
were drawn to the evolutionarily informed conceptual framework upon which TLC was 
developed – typically describing it as very believable and something that “just makes 
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sense”.  Consequently, it is possible that the compelling theoretical rationale of TLC, 
coupled with a pre-existing patient interest in adopting a healthier lifestyle, resulted in a 
sample of participants with uncharacteristically high motivation for treatment adherence.  
Effect of Personality Pathology on TLC Treatment Outcome  
 It was further hypothesized, based on the existing literature (Frank et al, 1987; 
Pilkonis & Frank, 1988; Ilardi & Craighead, 1995; Reich & Vasile, 1993; Shea et al., 
1992; Whisman, 1993), that the presence of comorbid Axis II personality disorder would 
have a negative impact on treatment response.  This hypothesis found only modest 
support in the present investigation.  Depressed patients with and without a comorbid PD 
diagnosis experienced a similar rate of improvement in depressive symptomatology over 
the course of treatment.  In addition, no significant covariation was observed between the 
overall magnitude of personality pathology (as indicated by a dimensional PD score) and 
treatment outcome.  Consistent with the extensive literature on cognitive therapy for 
depression – in which personality-disordered patients generally respond every bit as 
favorably as do those without personality pathology (Hirani, 2007; Saulsman et al., 2006; 
Van den Hout et al., 2006) – it is possible that TLC is specifically beneficial in the 
treatment of depression among patients with comorbid PD largely because of its highly 
structured, time-limited, and problem-focused nature.   
 Although no global effect of comorbid PD on TLC treatment response was 
observed, the study does provide evidence that TLC treatment outcome may vary as a 
function of specific Axis II disorders or domains.  Specifically, despite similar levels of 
treatment adherence in comparison with the rest of the study sample, patients with 
elevated levels of personality pathology on either Cluster A or Cluster B responded 
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significantly less well to TLC, even when controlling for initial depression severity.  This 
finding may be explained, in part, by the failure of TLC elements to adequately target 
important features of Cluster A and Cluster B pathology, such as affective dysregulations 
and substantial interpersonal difficulties.  The characterological difficulties associated 
with Cluster A and Cluster B pathology tend to engender a relatively high number of 
negative life events and crises, real or perceived, that can trigger a sustained level of 
distress capable of exacerbating or maintaining depression (Flett, Hewitt, Endler, & 
Bagby, 1995; Segal, Shaw, Vella, & Katz, 1992; Whisman, 1993).  Consequently, it is 
possible that although such personality-disordered patients are similarly motivated and 
adherent in comparison with the rest of the study sample, they do not respond as well due 
to an enduring experience of interpersonal chaos (and associated affective instability) not 
directly addressed in treatment.   
 Comorbid Cluster C pathology, which is characterized by high trait anxiety and 
neuroticism, was not shown to have a significant impact on TLC treatment outcome.  
Interestingly, a number of TLC elements may also inadvertently target features of Cluster 
C pathology that could serve as an impediment to treatment adherence and response.  For 
example, it is likely that the anti-ruminative strategies promoted in TLC not only have an 
effect on depressive symptomatology, but – via their effect in limiting anxiogenic 
rumination – also serve to reduce anxiety and neuroticism associated with the chronic 
activation of negative schemas that characterize Cluster C pathology.  In addition, it is 
likely that the exercise component of TLC results in a reduction of anxiety (McDonald & 
Hodgdon, 1991) in this personality-disordered group of patients.  Moreover, the structure 
of TLC, noted above, likely has a positive effect on Cluster C pathology.  Specifically, 
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the group format may be especially beneficial, since it often serves as a forum for patients 
to share with fellow group members their anxieties, identify with each other’s worries, 
and receive support and assistance in challenging dysfunctional cognitions related to their 
anxieties.  Thus, the study findings suggest that by concurrently addressing their 
depressive symptomatology and Cluster C personality pathology, TLC effectively treats 
depression in this specific comorbid population. 
 It should also be noted that the failure of overall personality pathology (i.e., 
aggregate dimensional score) to significantly predict treatment outcome in the present 
study may be due to the participant sample being fairly “top-heavy” with Cluster C 
pathology.  That is, a significant proportion of patients (50%) in the sample met 
diagnostic criteria for a Cluster C PD, while only 13 patients (19%) received a diagnosis 
of either Cluster A or Cluster B PD.  The study’s explicit exclusion of individuals with 
psychotic symptoms, substance abuse diagnoses, a history of self-harm behavior during 
the past two years, or active suicidal ideation likely precluded several depressed patients 
with Cluster A or Cluster B PD’s from participating.  Thus, the relative effectiveness of 
TLC in the treatment of depression in patients with comorbid Cluster C PD, and the high 
proportion of Cluster C-disordered individuals in the PD group, may have obscured 
detection of a possible adverse effect of overall personality pathology on treatment 
outcome. 
Effect of Adherence on TLC Treatment Outcome 
 The hypothesis that adherence to the TLC treatment protocol would predict 
treatment response was supported.  As expected, patients who exhibited higher levels of 
compliance tended to report significantly lower levels of depressive symptomatology on 
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the primary outcome measure, the BDI-II, after controlling for initial depression severity 
and personality pathology.  This finding is consistent with the hypothesis that adherence 
to the TLC protocol, rather than the indirect effect of nonspecific treatment factors like 
enhanced positive expectancies associated with merely being in treatment (Frank, 1973), 
is responsible, to some degree, for the observed reduction in depression experienced by 
the patients in the sample. 
 It should also be noted that in the study’s evaluation of adherence to specific TLC 
components, only exercise adherence was found to yield significant prediction of 
treatment outcome, after controlling for initial depression severity (i.e., baseline BDI-II) 
and overall level of personality pathology (i.e., dimensional PD score).  For every 
additional 27 minutes exercised each week, patients experienced an additional 3.3 point 
reduction in depressive symptomatology (BDI-II).  This study finding suggests that the 
reduction in depressive symptomatology observed as a result of adherence to the TLC 
protocol may be driven to a considerable extent by adherence to the exercise component.  
This finding, in turn, raises the question of whether all six primary components of the 
TLC protocol are necessary.  It is possible that some components of TLC do not 
contribute significant unique variance in the prediction of treatment outcome sufficient to 
warrant inclusion in the protocol.  Alternatively, it may be that the relatively truncated 
range of adherence rates to some protocol elements – e.g., the 90% rate of overall 
adherence to omega-3 supplementation – attenuated the likelihood of detecting adherence 
effects in this investigation.  It is also worth bearing in mind that the present study, with 
only 68 participants (and 58 treatment completers), was not adequately powered to detect 
beneficial small-to-medium-sized effects attributable to specific protocol elements. 
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Mediation 
 Study findings suggest that adherence to TLC treatment (or lack thereof) does not 
mediate the adverse effect of personality pathology (Clusters A and B) on treatment 
outcome.  Instead, it is likely that the characterological issues associated with specific 
clusters of Axis II PD determine, in large part, the effect of personality pathology on 
treatment response.  For example, it is believed that the unaddressed affective 
dysregulations and considerable interpersonal difficulties typically observed in patients 
with Cluster A and Cluster B are responsible, in large part, for the differential treatment 
outcome observed. 
Limitations 
The present study is characterized by several important limitations.  One notable 
limitation concerns the incompleteness of study adherence data.  As previously noted, 
sleep adherence data were not included in study analyses, as they were considered 
problematic due to their significant conflation with depressive symptomatology. (In other 
words, a patient’s failure to obtain the protocol’s recommended nightly duration of sleep 
could reflect the enduring effects of depression rather than a genuine lack of adherence.)  
Consequently, one of the six primary components of the TLC protocol was omitted from 
study analyses.  It is quite possible, however, that the inclusion of sleep adherence data 
would not have made a significant difference in study results, inasmuch as: (a) sleep 
enhancement receives considerably less emphasis in the protocol than other TLC 
elements; (b) it is the last element introduced in treatment (at Session 6); and (c) three 
other elements of treatment – omega-3, bright light, and exercise – have a documented 
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potential of enhancing sleep quality and quantity (Fetveit, Skjerve, & Bjorvatn, 2003; 
Stevens et al., 1996; Trivedi, Greer, Grannemann, Chambliss, & Jordan, 2006)).   
Another limitation of the present study was the study’s relatively modest sample 
size (68 participants, and 58 treatment completers), which did not afford adequate power 
to detect beneficial small-to-medium-sized effects.  It is also important to note that the 
Weekly Record Form (WRF) was revised after the present investigation was already 
under way – specifically, following completion of the first two treatment groups.  
Consequently, social support data was not collected for the first 18 study patients.  It is 
assumed that these missing data should not significantly affect the analyses, as they are 
“missing at random” – i.e., there is no reason to believe that the first two TLC groups 
significantly differ from the rest of the sample on this variable.  Nevertheless, the absence 
of these data constitutes a study limitation. 
 Also, the observed internal consistency of the WRF was indicative of an 
acceptable, but not ideal, level of reliability.  It is possible that the WRF’s merely 
moderate internal reliability is not a measurement problem, but rather a result of the 
phenomenon that people’s adherence truly varies across the protocol’s different treatment 
elements.  Such idiosyncratic adherence across domains is consistent with the subjective 
self-report of numerous study patients.  For example, several patients have discovered the 
exercise component of TLC to be the most difficult to adhere to while others have found 
it to be the easiest.  Consequently, there is reason to believe that there is some domain- 
specific variability involved in the adherence construct in addition to the common 
variance.   
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 Finally, the methodology for obtaining the study sample – inclusion and exclusion 
criteria, in addition to recruitment secondary to news media coverage – also introduces 
some important limitations.  It is likely, for example, that the study exclusion criteria 
resulted in a sample that had a restricted range of personality-disordered patients, with 
relatively few who met diagnostic criteria for Axis II disorders on Clusters A and B.  It is 
possible that this selectivity of the sample was responsible, in part, for the failure to 
observe an effect of overall personality pathology on treatment outcome.  In addition, the 
recruitment of volunteers for a well-publicized “holistic” treatment for depression may 
have resulted in a group of extraordinarily motivated patients.  Thus, these sample issues 
limit the ability to generalize the study’s findings to other depressed populations.  
Future Directions 
 Due to the limitations outlined above, a replication that addressed these 
shortcomings would be beneficial to corroborate the present study’s findings.  Moreover, 
the results of this investigation suggest that future studies in the field should avoid 
“lumping” clusters of Axis II personality disorders together to form a single, monolithic 
PD group.  The differential treatment effects observed for depressed patients with either 
comorbid Cluster A or Cluster B personality pathology underscores the notion that 
clusters of Axis II PD’s are not homogenous groups that can be combined.  It is likely 
that particular characteristics associated with certain clusters affects treatment response in 
distinct ways.  Consequently, combing PD clusters produces excess noise that limits the 
detection of differential treatment effects.  Furthermore, the combination of PD clusters 
into a single PD group may explain, in part, the notable inconsistency of reported 
outcomes in the empirical literature. 
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In the same vein, future investigations should move toward increased specificity 
with respect to the effects of personality pathology.  That is, evaluation of specific PD’s 
may well uncover that treatment response varies appreciably as a function of each 
disorder.  The information generated from these studies will also have the potential to 
enhance treatment of comorbid PD populations.  The identification of pretreatment 
clinical characteristics that significantly impact treatment outcome may be used to guide 
treatment choices and lead to more effective interventions.   
 The deleterious effects of comorbid Cluster A and Cluster B pathology on TLC 
treatment outcome observed in the study warrant a discussion of possible modifications 
to the TLC protocol to render it more efficacious for the this subset of patients.  It should 
be noted that almost 20% of patients in the total study sample met diagnostic criteria for 
either a Cluster A or a Cluster B PD.  Moreover, the general depressed population may be 
comprised of an even higher proportion of individuals with a comorbid Cluster A or 
Cluster B PD (Casey et al., 2004).  Thus, the study findings suggest that a sizable subset 
of depressed individuals do not respond as favorably as depressed individuals without 
comorbid Cluster A or Cluster B PD’s to TLC.  Consequently, a modification of the TLC 
protocol would be clinically useful. 
 It is posited that the characterological issues typically observed in depressed 
individuals with comorbid Cluster A or Cluster B pathology, namely affective 
dysregulation, interpersonal chaos, and the experience of numerous negative life events 
(e.g., failures, crises, etc), have an adverse effect on treatment outcome for TLC for 
depression.  Thus, increased attention devoted to addressing these issues will likely lead 
to more favorable treatment response for these comorbid populations.   
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 Lengthening the TLC treatment may be needed to adequately address patients’ 
characterological issues and to limit their deleterious influence on patient response to 
TLC for depression.  For example, a session could be included that focused on 
understanding this comorbid population’s vulnerabilities and nurturing their strengths.  In 
addition, it would be beneficial for patients to learn strategies that more directly target 
their characterological difficulties and to receive assistance in coping with the chronic 
stressors that they encounter regularly.  Furthermore, therapist phone calls to patients 
could be lengthened or conducted more frequently to provide more opportunities to 
address and minimize the influence of specific characterological issues on treatment 
outcome.  Finally, treating depressed patients with comorbid Cluster A or Cluster B 
pathology with concurrent individual therapy may yield a more favorable treatment 
response.  Future studies that evaluate modifications to TLC treatment to more 
effectively treat these comorbid populations may prove worthwhile; however, the clinical 
trials to examine a differential effect of a refined treatment would have to be very large as 
the effect size is likely to be small. 
 Given the study finding that exercise was the only domain in which adherence 
significantly predicted treatment outcome, future component analyses of the TLC 
protocol appear warranted.  First, future studies that included less problematic sleep 
adherence data would be useful.  In addition, it is possible that the decision in the present 
study to cap the adherence data – i.e., to impose an upper bound of 100% on adherence 
for each element, even if a patient actually exceeded protocol’s recommended daily 
“dosage” for any given element – limited the variance in treatment outcome that could be 
predicted.  That is, a patient in this study who received thirty minutes of bright light each 
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day and a patient that received sixty minutes of bright light were both considered 100% 
compliant on this component.  However, it is plausible that these two patients are 
experiencing different levels of antidepressant effect from the bright light exposure and 
utilization of this adherence data will lead to an increase in predicted variance that would 
provide a clearer picture of which TLC components significantly predict treatment 
outcome.  Furthermore, dismantling studies that more closely evaluated the “need” of 
each TLC component may lead to a worthwhile conservation of resources. 
 Finally, the present study did not include follow-up data (although such data are 
being collected by study researchers for future analysis).  It has been documented that 
differences in treatment outcome according to PD diagnosis tends to be more prominent 
after long-term follow-up compared to short-term outcome (Cyranowski et al., 2004; 
Saulsman et al., 2006).  Thus, it is important for future studies to assess not only who gets 
better after treatment, but who maintains treatment gains.  It is possible that the enduring 
characterological issues associated with comorbid Cluster A and Cluster B pathology that 
influenced TLC treatment response in this study also confer an increased vulnerability to 
future relapse.  In addition, it’s possible that although depressed patients with comorbid 
Cluster C pathology respond to TLC at a comparable rate to patients without comorbid 
Axis II pathology, the Cluster C-disordered patients exhibit differential relapse rates.  
These are important questions that need to be answered. 
 The present study’s findings are consistent with an emerging literature on the 
influence of Axis II personality disorder on depression, which suggests that the presence 
of a comorbid PD may not have a significant effect on short-term treatment response 
(Hirani, 2007; Mulder, 2002; Mulder et al., 2003).  However, after a closer examination 
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of personality pathology, the study findings indicate that comorbid Cluster A and Cluster 
B personality pathology should be viewed as negative treatment indicators for TLC for 
depression.  In the end, this study facilitates understanding of the impact of co-occurring 
PD on treatment adherence and outcome of TLC for depression.  This, in addition to the 
knowledge generated by future investigations in this field, should lead to more effective 
treatment of depression in this comorbid population. 
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Appendix A    Therapeutic Lifestyle Change for Depression Record Form 
 Tuesday Wednesday Thursday Friday Saturday Sunday Monday 
W
e
e
k
 
1
4
 
May 16 
 
Omega-3:  
Full  Partial  None 
Multivitamin: Y   N 
Bright Light: 
 # of min: _________ 
Sleep: 
 # of hr: __________ 
 Disturbances: 
  Onset  Middle  Late 
 Restful:   Y   N 
 Strategies:   Y   N 
 Helpful:   Y   N 
Exercise: 
 Type: ___________ 
 # of min: ________ 
 Pulse: ___________ 
Pleasant Activity: 
   Y   N   
 Expected: _______ 
 Actual:  _________ 
FLOW Activity: 
   Y   N 
Social Activity: 
 Contact Near:   Y  N 
 Activity: _________ 
 Contact Far:    Y   N 
Self-Esteem: 
1.    _____________ 
2. _____________ 
3. _____________ 
Daily Mood Rating: 
 1  2  3  4  5  6  7  8  9  10 
Poor  -  -  -  -  - Good 
May 17 
 
Omega-3:  
Full  Partial  None 
Multivitamin: Y   N 
Bright Light: 
 # of min: _________ 
Sleep: 
 # of hr: __________ 
 Disturbances: 
  Onset  Middle  Late 
 Restful:   Y   N 
 Strategies:   Y   N 
 Helpful:   Y   N 
Exercise: 
 Type: ___________ 
 # of min: ________ 
 Pulse: ___________ 
Pleasant Activity: 
   Y   N   
 Expected: _______ 
 Actual:  _________ 
FLOW Activity: 
   Y   N 
Social Activity: 
 Contact Near:   Y  N 
 Activity: _________ 
 Contact Far:    Y   N 
Self-Esteem: 
1.  _____________ 
2.  _____________ 
3.  _____________ 
Daily Mood Rating: 
 1  2  3  4  5  6  7  8  9  10 
Poor  -  -  -  -  - Good 
 
May 18 
 
Omega-3:  
Full  Partial  None 
Multivitamin: Y   N 
Bright Light: 
 # of min: _________ 
Sleep: 
 # of hr: __________ 
 Disturbances: 
  Onset  Middle  Late 
 Restful:   Y   N 
 Strategies:   Y   N 
 Helpful:   Y   N 
Exercise: 
 Type: ___________ 
 # of min: ________ 
 Pulse: ___________ 
Pleasant Activity: 
   Y   N   
 Expected: _______ 
 Actual:  _________ 
FLOW Activity: 
   Y   N 
Social Activity: 
 Contact Near:   Y  N 
 Activity: _________ 
 Contact Far:    Y   N 
Self-Esteem: 
1.  _____________ 
2.  _____________ 
3.  _____________ 
Daily Mood Rating: 
 1  2  3  4  5  6  7  8  9  10 
Poor  -  -  -  -  - Good 
 
 
May 19 
 
Omega-3:  
Full  Partial  None 
Multivitamin: Y   N 
Bright Light: 
 # of min: _________ 
Sleep: 
 # of hr: __________ 
 Disturbances: 
  Onset  Middle  Late 
 Restful:   Y   N 
 Strategies:   Y   N 
 Helpful:   Y   N 
Exercise: 
 Type: ___________ 
 # of min: ________ 
 Pulse: ___________ 
Pleasant Activity: 
   Y   N   
 Expected: _______ 
 Actual:  _________ 
FLOW Activity: 
   Y   N 
Social Activity: 
 Contact Near:   Y  N 
 Activity: _________ 
 Contact Far:    Y   N 
Self-Esteem: 
1.  _____________ 
2.  _____________ 
3.  _____________ 
Daily Mood Rating: 
 1  2  3  4  5  6  7  8  9  10 
Poor  -  -  -  -  - Good 
 
May 20 
 
Omega-3:  
Full  Partial  None 
Multivitamin: Y   N 
Bright Light: 
 # of min: _________ 
Sleep: 
 # of hr: __________ 
 Disturbances: 
  Onset  Middle  Late 
 Restful:   Y   N 
 Strategies:   Y   N 
 Helpful:   Y   N 
Exercise: 
 Type: ___________ 
 # of min: ________ 
 Pulse: ___________ 
Pleasant Activity: 
   Y   N   
 Expected: _______ 
 Actual:  _________ 
FLOW Activity: 
   Y   N 
Social Activity: 
 Contact Near:   Y  N 
 Activity: _________ 
 Contact Far:    Y   N 
Self-Esteem: 
1.  _____________ 
2.  _____________ 
3.  _____________ 
Daily Mood Rating: 
 1  2  3  4  5  6  7  8  9  10 
Poor  -  -  -  -  - Good 
 
May 21 
 
Omega-3:  
Full  Partial  None 
Multivitamin: Y   N 
Bright Light: 
 # of min: _________ 
Sleep: 
 # of hr: __________ 
 Disturbances: 
  Onset  Middle  Late 
 Restful:   Y   N 
 Strategies:   Y   N 
 Helpful:   Y   N 
Exercise: 
 Type: ___________ 
 # of min: ________ 
 Pulse: ___________ 
Pleasant Activity: 
   Y   N   
 Expected: _______ 
 Actual:  _________ 
FLOW Activity: 
   Y   N 
Social Activity: 
 Contact Near:   Y  N 
 Activity: _________ 
 Contact Far:    Y   N 
Self-Esteem: 
1.  _____________ 
2.  _____________ 
3.  _____________ 
Daily Mood Rating: 
 1  2  3  4  5  6  7  8  9  10 
Poor  -  -  -  -  - Good 
 
May 22 
 
Omega-3:  
Full  Partial  None 
Multivitamin: Y   N 
Bright Light: 
 # of min: _________ 
Sleep: 
 # of hr: __________ 
 Disturbances: 
  Onset  Middle  Late 
 Restful:   Y   N 
 Strategies:   Y   N 
 Helpful:   Y   N 
Exercise: 
 Type: ___________ 
 # of min: ________ 
 Pulse: ___________ 
Pleasant Activity: 
   Y   N   
 Expected: _______ 
 Actual:  _________ 
FLOW Activity: 
   Y   N 
Social Activity: 
 Contact Near:   Y  N 
 Activity: _________ 
 Contact Far:    Y   N 
Self-Esteem: 
1. _____________ 
2. _____________ 
3. _____________ 
Daily Mood Rating: 
 1  2  3  4  5  6  7  8  9  10 
Poor  -  -  -  -  - Good  
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